Published online Sep 9, 2026. doi: 10.5409/wjcp.117421
Revised: December 24, 2025
Accepted: March 17, 2026
Published online: September 9, 2026
Processing time: 236 Days and 1 Hours
Autoimmune diseases in children, including type 1 diabetes, celiac disease, and juvenile arthritis, represent a growing global health challenge. This surge, too rapid to be explained by genetic shifts alone, highlights the critical role of environmental factors and underscores the urgent need for proactive prevention. This review presents an integrated, evidence-based framework for preventing pedia
Core Tip: The rising global incidence of pediatric autoimmune diseases necessitates a strategic shift from reactive disease management to proactive prevention. This article outlines a comprehensive, integrated framework that leverages advances in genomics and exposomics to identify and intervene in high-risk children. The model begins with primordial prevention during the first 1000 days, progressing through primary and secondary interventions, and concluding with aggressive therapy for established disease. By adopting this tiered approach, clinicians, researchers, and public health officials can work collaboratively to alter disease trajectories, reduce the long-term burden of these conditions, and ultimately improve the health outcomes for future generations.
- Citation: Al-Beltagi M, Saeed NK, Bediwy AS, Bediwy EA, Elbeltagi R. From genes to environment: A life-course approach to prevent pediatric autoimmune diseases. World J Clin Pediatr 2026; 15(3): 117421
- URL: https://www.wjgnet.com/2219-2808/full/v15/i3/117421.htm
- DOI: https://dx.doi.org/10.5409/wjcp.117421
Autoimmune diseases in children, such as type 1 diabetes mellitus (T1DM), celiac disease, autoimmune thyroiditis, juvenile idiopathic arthritis (JIA), inflammatory bowel disease (IBD), and systemic lupus erythematosus (SLE), represent a growing global health challenge with a significant public health threat[1]. Over the past few decades, the incidence of these conditions has risen markedly across diverse geographic regions, affecting both developed and developing countries. For example, T1DM incidence is increasing annually by approximately 3%-5% in many populations, while celiac disease prevalence has more than quadrupled in some cohorts[2]. In addition, the prevalence of positive antinuclear antibody (ANA - a common biomarker of autoimmunity) was tripled in adolescents from 1988 to 2012. Similar upward trends are observed for autoimmune thyroiditis, IBD, and juvenile arthritis, contributing to substantial morbidity, healthcare costs, and lifelong treatment burdens in affected children[3]. This surge, occurring too rapidly to be explained by genetic shifts alone, underscores the profound impact of environmental changes and the urgent need for practical, proactive, evidence-based preventive strategies[4]. However, it is essential to critically evaluate the certainty of these epidemiological conclusions. While the upward trajectory of pediatric autoimmunity appears genuine, several confounders may influence the reported magnitude of these trends. Improved diagnostic ascertainment - driven by increased clinical awareness and the broader availability of high-sensitivity biomarkers - along with evolving classification criteria (such as the 'no-biopsy' diagnostic pathway for pediatric celiac disease) likely contribute to the observed surge[5]. Additionally, selection biases in large longitudinal cohort studies, which often focus on high-resource settings or families with a pre-existing history of autoimmunity, may limit the generalizability of these findings. Consequently, the reported ‘surge’ likely reflects a complex combination of genuine biological shifts in the pediatric exposome and improved detection capabilities in modern healthcare systems[6].
The pathophysiology of pediatric autoimmune diseases represents a multi-step “cascade” in which generalized immune dysregulation is funneled into organ-specific pathology by distinct genetic and environmental inputs (Figure 1). While conditions such as T1DM, celiac disease, and IBD share a foundational “primordial” risk - including human leukocyte antigen (HLA)-mediated susceptibility and gut dysbiosis - their clinical trajectories diverge at the point of antigen-specific activation[7]. For instance, whereas T1DM is driven by T-cell-mediated destruction of pancreatic beta cells, often triggered by enteroviral infections, celiac disease is uniquely dependent on dietary gluten as the requisite environmental antigen. This comparative understanding is critical for clinical practice; universal primordial strategies (e.g., breastfeeding, vitamin D sufficiency) aim to stabilize the broader immune regulatory network, while disease-specific secondary prevention [e.g., screening for anti-tissue transglutaminase (tTG) or islet autoantibodies] is required to intercept the specific pathological cascade before irreversible tissue damage occurs[8,9].
The pathophysiology of pediatric autoimmune diseases reflects a complex interplay between genetic predisposition and environmental influences. Genetic susceptibility is often conferred by specific genetic variants, most notably HLA haplotypes such as HLA-DR3, HLA-DR4, and HLA-DQ2/DQ8, which increase baseline risk. However, possessing these risk genes is not deterministic[10]. The transition from genetic predisposition to clinical disease is heavily modulated by environmental factors. Viral and bacterial infections, gut microbiome disturbances (dysbiosis), early-life dietary exposures (e.g., timing of gluten introduction, cow’s milk proteins), vitamin D deficiency, and environmental toxins, such as endocrine disruptors, can precipitate immune dysregulation in genetically susceptible individuals. This interaction culminates in the loss of self-tolerance, production of autoantibodies, and ultimately, progressive autoimmune-mediated tissue destruction[11].
Emerging evidence underscores the importance of the “first 1000 days” - from conception to a child’s second birthday - as the most critical window for shaping immune tolerance and establishing a balanced gut microbiome (Figure 2). During this period, the infant’s immune system and gut microbiome are co-developing and are exquisitely sensitive to external exposures[12]. The resulting immune system programming is particularly sensitive to maternal health, mode of delivery, breastfeeding, complementary feeding practices, exposure to infections, and antibiotic use. Perturbations in these early-life factors may create a pro-inflammatory state and tilt the immune balance toward autoimmunity, particularly in high-risk children[13]. Thus, targeted interventions during this window hold promise for modifying disease trajectories before the onset of irreversible immune-mediated injury, making it the prime opportunity for preventive interventions[14]. Figure 3 illustrates the link among genetic susceptibility, environmental triggers, and early-life factors, as well as pre
This review aims to provide an integrated, evidence-based framework for preventing autoimmune diseases in high-risk pediatric populations. Prevention strategies will be examined across the entire care spectrum, from primordial to tertiary prevention. Primordial prevention focuses on upstream societal and environmental factors to reduce exposure to risk elements before disease pathways are triggered. Primary prevention targets at-risk children to prevent the develop
Identifying children at heightened risk for autoimmune disease is the foundational step for targeted prevention, requiring a multi-dimensional approach that integrates genetic, immunological, and environmental data. The most accessible indicator remains family history, as a child with a first-degree relative with an autoimmune condition carries a substantially elevated lifetime risk[17]. This familial clustering is rooted in genetic susceptibility, primarily conferred by specific HLA class II haplotypes that govern antigen presentation to T cells. For instance, the HLA-DR3-DQ2 and DR4-DQ8 haplotypes are powerfully associated with T1DM and celiac disease, while other alleles are linked to JIA and lupus[18]. While essential, genetic predisposition is not deterministic; most individuals who carry high-risk HLA genes never develop clinical disease. This crucial gap underscores the need to look beyond genetics to identify children in whom the autoimmune process has already begun[19].
The transition from genetic predisposition to active disease is best characterized by immune biomarkers that signal a shift toward preclinical autoimmunity. This asymptomatic phase is characterized by the presence of disease-specific autoantibodies in circulation, reflecting a definitive breach of self-tolerance, long before clinical symptoms emerge[20]. In T1DM, the appearance of two or more islet autoantibodies [against glutamic acid decarboxylase 65 (GAD65), islet antigen-2 (IA-2), or insulin, for example] signifies a near-certain progression to overt disease[21]. Similarly, anti-tTG antibodies in celiac disease or antinuclear antibodies (ANA) in lupus serve as powerful predictive markers. Landmark longitudinal studies, such as The Environmental Determinants of Diabetes in the Young, have meticulously mapped this progression, demonstrating that seroconversion is a critical event that dramatically increases an individual’s risk profile and presents a key window for secondary prevention[22].
The most sophisticated and accurate risk stratification is achieved through integrated risk models that combine genetic and biomarker data with a third critical layer: Environmental context. These advanced models often utilize polygenic risk scores (PRS), which aggregate the minor effects of hundreds or thousands of genetic variants (both HLA and non-HLA) into a single, quantitative measure of inherited susceptibility[23]. This genetic score is then layered with biomarker status and data on relevant environmental exposures, such as perinatal factors (e.g., mode of delivery), a history of specific viral infections (e.g., coxsackievirus), dietary patterns, and gut microbiome signatures associated with immune dysregulation[24]. By merging these data streams, a holistic and dynamic risk profile can be constructed, enabling clinicians to stratify children with far greater precision. For example, a child with a high PRS and positive autoantibodies who experiences a known environmental trigger would be classified at the highest tier of risk, justifying enrollment in clinical trials for targeted preventive therapies[25]. This multi-layered, precision-based approach is essential for tailoring the surveillance schedules and interventions discussed in the subsequent sections of this review. Table 1 summarizes the common pediatric autoimmune disorders and their associated genetic and biomarker risk factors.
| Autoimmune disorder | Prevalence/incidence (children) | Typical age of onset | Key genetic risk factors | Biomarker risk (preclinical) | Clinical notes |
| T1DM | Incidence approximately 10-60 per 100000/year (region-dependent) | Peaks 4-7 and 10-14 years | HLA-DR3, HLA-DR4, DR3/DR4; HLA-DQ8; INS, PTPN22, CTLA4 | ≥ 2 islet autoantibodies (IAA, GAD65, IA-2, ZnT8) → high progression risk | Autoantibodies may precede the onset by years; a strong family history signal |
| Celiac disease | Prevalence approximately 0.5%-1.5% | After gluten introduction, commonly 1-3 years (but any age) | HLA-DQ2 (especially DQ2.5), HLA-DQ8; IL2/IL21, CTLA4 | Anti-tTG IgA, EMA IgA, DGP antibodies | Serology plus histology (or no-biopsy pathway in select pediatric cases) |
| Autoimmune thyroid disease (Hashimoto’s/Graves’) | Prevalence approximately 1%-2% in adolescents (higher in females) | Late childhood to adolescence (8-18 years) | HLA-DR3/DR5; CTLA4, PTPN22, FOXP3 | Anti-TPO, anti-Tg; TRAb in Graves’ | Presents with hypo- or hyperthyroidism; consider screening in T1DM/celiac |
| JIA | Prevalence approximately 30-200 per 100000; incidence 5-20 per 100000/year | < 16 years; peaks 1-3 and 8-12 years (subtype-dependent) | HLA-DRB1 “shared epitope” alleles; PTPN22; STAT4; HLA-B27 (ERA subtype) | ANA (oligoarticular), RF and anti-CCP (polyarticular) | ANA positivity common in oligoarticular JIA; HLA-B27 → enthesitis-related arthritis |
| Inflammatory bowel disease (Crohn’s, UC) | Prevalence approximately 100-300 per 100000; incidence 5-15 per 100000/year | Peak 10-17 years; can occur earlier | NOD2/CARD15 (Crohn’s), IL23R, ATG16 L1 | ASCA (Crohn’s), pANCA (UC) | Biomarkers aid differentiation: PANCA (UC) vs ASCA (Crohn’s); growth failure can be presenting sign |
| Systemic lupus erythematosus | Prevalence approximately 3-20 per 100000; incidence approximately 0.3-0.9 per 100000/year | Usually 12-16 years; rare < 5 years | HLA-DR2/DR3; IRF5, STAT4; complement (C1q/C4) deficiency | ANA, anti-dsDNA, anti-Sm; low C3/C4 | ANA highly sensitive, not specific; anti-dsDNA correlates with activity; multi-organ involvement |
| Autoimmune hepatitis | Incidence approximately 0.3-1 per 100000/year (rare) | Bimodal; childhood 7-15 years (types 1 and 2) | Corrected: HLA-DRB1*03/04 (type 1), HLA-DRB107/*13 (type 2) | ANA, SMA (type 1); anti-LKM1 (type 2) | Type 1 ANA/SMA; type 2 anti-LKM1; may present with acute hepatitis or insidious transaminitis |
| Myasthenia gravis (juvenile) | Prevalence approximately 1-5 per 100000; incidence approximately 0.1-0.4 per 100000/year | Peaks in prepubertal (5-10 years, often ocular) and adolescence (10-18 years) | HLA-B8, HLA-DR3 | Anti-AChR antibodies; anti-MuSK antibodies (subset) | Fluctuating fatigable weakness; ocular symptoms common initially; thymic abnormalities less frequent than adults |
| Pediatric-onset multiple sclerosis | Prevalence approximately 1-5 per 100000; incidence approximately 0.1-0.3 per 100000/year | 10-17 years (rare < 10) | HLA-DRB1*15:01; IL7R | CSF oligoclonal bands; MOG-IgG in MOGAD phenotype | Usually relapsing-remitting; MRI dissemination in time/space; consider EBV seropositivity context |
| Juvenile dermatomyositis | Prevalence 2-4 per 100000; incidence 02-0.5 per 100000/year | Peak 4-10 years | HLA-DQA105:01, HLA-DRB103 | Myositis-specific antibodies (e.g., anti-Mi-2, anti-TIF1-γ [p155/140]) | Symmetric proximal weakness, heliotrope rash, Gottron papules; risk of calcinosis; nailfold capillary changes |
Primordial prevention aims to halt the emergence of modifiable risk factors for autoimmunity before they arise, focusing on maternal, perinatal, and early postnatal influences that shape immune tolerance. The “first 1000 days” - spanning conception through the second year of life - represent a critical window during which the immune system, gut mic
Prenatal maternal health optimization is the cornerstone of this approach. Adequate intake of micronutrients such as vitamin D, omega-3 fatty acids, and folate during pregnancy supports optimal fetal immune and neural development. Vitamin D sufficiency is associated with a reduced risk of T1DM and other autoimmune conditions in offspring, likely through modulation of T-cell differentiation and reduced production of pro-inflammatory cytokines[28]. Omega-3 fatty acids contribute to the production of anti-inflammatory lipid mediators, while folate is critical for DNA methylation patterns involved in immune tolerance[29]. Maternal avoidance of harmful exposures - including tobacco smoke, alcohol, and endocrine-disrupting chemicals such as bisphenol A (BPA) and phthalates - is equally important, as these agents have been linked to immune dysregulation, altered thymic function, and increased risk of allergic and autoimmune diseases[30].
Mode of delivery is another key determinant of early immune programming. Vaginal birth provides the first major inoculation of beneficial microbes, which is crucial for training the infant’s immune system. Vaginal birth facilitates vertical transfer of maternal vaginal and intestinal microbiota to the newborn, seeding a diverse and balanced gut microbial community essential for immune tolerance development[31]. In contrast, cesarean section bypasses this exposure, leading to delayed colonization by beneficial bacteria such as Bacteroides and Bifidobacterium and increased dominance of skin-associated microbes (Figure 5). This altered microbial trajectory has been associated with heightened risk of autoimmune and allergic conditions in observational studies, though causality remains under investigation. Strategies such as microbiota restoration at birth (e.g., vaginal seeding) are being explored, though their safety and efficacy are not yet established[32].
Early-life microbiome protection continues beyond birth. Exclusive breastfeeding for the first six months provides not only optimal nutrition but also critical immunological components. Breast milk is a living fluid packed with immunological components that protect the infant and cultivate a healthy gut microbiome[33]. It contains secretory immunoglobulin A, which coats mucosal surfaces and prevents pathogen adhesion; human milk oligosaccharides, which selectively nourish beneficial gut bacteria; lactoferrin, lysozyme, and defensins with antimicrobial activity; and viable immune cells that can influence mucosal immune maturation (Figure 6)[34]. Skin-to-skin contact enhances microbial transfer from mother to infant and promotes thermoregulation and bonding. Minimizing unnecessary antibiotic use in early life helps preserve microbial diversity and functional capacity, thereby avoiding disruptions that increase au
Creating a healthy early-life environment is another pillar of primordial prevention. Reducing exposure to air pollution, indoor particulate matter, and passive tobacco smoke reduces the inflammatory load and oxidative stress, thereby perturbing immune tolerance pathways[36]. Avoidance of household chemical exposures - including volatile organic compounds, pesticides, and synthetic fragrances - further supports a balanced immune trajectory[37]. Collectively, these environmental optimizations act synergistically to reduce the likelihood of maladaptive immune priming that could trigger autoimmunity in genetically susceptible children. By integrating maternal health optimization, microbiome-supportive birth and feeding practices, and environmental toxin reduction, primordial prevention addresses autoimmune risk at its root - before the earliest precursors of disease emerge[38].
While there’s no guaranteed way to prevent autoimmune disorders in children through diet alone, dietary strategies are among the most accessible and modifiable tools for preventing the onset of autoimmune disease in genetically susceptible children by addressing underlying factors and supporting overall well-being. Nutrition plays a central role in the primary prevention of autoimmunity, particularly in children with a strong genetic predisposition. Dietary exposures influence immune tolerance by modulating systemic inflammation, gut microbiome diversity, and intestinal barrier function[39]. A Western dietary pattern - characterized by high intake of refined sugars, sweetened beverages, processed meats, and ultra-processed foods rich in inflammatory fats and additives - has been linked to gut microbiome dysbiosis, increased intestinal permeability, and upregulation of inflammatory mediators such as C-reactive protein and interleukin-6. Beyond being nutrient-poor, this diet promotes chronic low-grade inflammation, which may predispose susceptible children to immune dysregulation and autoimmunity[40].
Certain dietary choices can help support a healthy immune system and potentially reduce the risk or severity of these conditions. Mounting evidence suggests that an anti-inflammatory nutritional pattern, such as the Mediterranean diet, rich in fresh fruits, vegetables, legumes, whole grains, fish, nuts, seeds, healthy fats, and sources of lean protein, while minimizing processed food, can favorably influence immune homeostasis and reduce chronic low-grade inflammation, a known contributor to autoimmunity[41]. Minimizing intake of processed foods, refined sugars, saturated fats, and food additives is equally essential, as these have been linked to gut dysbiosis, metabolic stress, and pro-inflammatory immune responses. This approach provides abundant fiber to nourish the gut microbiome, phytochemicals with antioxidant activity, and essential micronutrients to meet the developmental demands of childhood[42]. In pediatric populations, anti-inflammatory diets have been associated with reductions in pain, morning stiffness, and inflammatory biomarkers in children with JIA, along with improvements in functional outcomes and increased fecal butyrate levels, suggesting both systemic and gut-mediated benefits[43].
Vitamin D plays a particularly prominent role in immune regulation. Beyond its classical effects on calcium and bone metabolism, it enhances regulatory T-cell function, promotes immune tolerance, and suppresses excessive pro-inflammatory cytokine release[44]. Observational studies have demonstrated associations between adequate vitamin D levels and reduced incidence of T1DM and multiple sclerosis, especially in populations at higher latitudes or with limited sun exposure. Preventive strategies that emphasize optimal vitamin D sufficiency during pregnancy, infancy, and childhood may therefore provide a low-cost, scalable means of reducing autoimmune risk[45,46].
Omega-3 fatty acids, predominantly eicosapentaenoic acid and docosahexaenoic acid, found in fatty fish and specific plant sources, further modulate the immune response by competing with pro-inflammatory omega-6 fatty acids in eicosanoid pathways. Their metabolites (resolvins and protectins) actively resolve inflammation, attenuate antigen-presenting cell activation, and reduce Th17-driven autoimmune pathways[47]. Supplementation during pregnancy and early life has been linked to lower rates of allergic sensitization and asthma, and emerging data suggest protective effects against autoimmune disorders such as rheumatoid arthritis and T1DM[48].
Dietary exposures in early life also shape immune tolerance. Historically, delaying exposure to allergens such as peanuts and eggs was thought to reduce the risk of allergy. Still, landmark clinical trials (e.g., Learning Early About Peanut Allergy and Enquiring About Tolerance studies) have reversed this paradigm. Introducing these foods during infancy promotes oral tolerance, training the immune system to recognize dietary proteins as safe rather than as threats (Figure 7). This paradigm offers a conceptual framework for how controlled dietary exposures during critical developmental windows could be applied to prevent broader immune-mediated diseases, not just allergies[49,50].
While no single “autoimmune diet” has been universally defined, nutritional strategies should be individualized with the overarching goal of optimizing gut health and reducing the body’s inflammatory burden. A widely adopted framework in pediatric autoimmune care is the 5R protocol, which provides a systematic approach to dietary and lifestyle modification (Figure 8)[51]. The first step, remove, focuses on eliminating nutritional triggers such as common allergens (wheat, dairy, eggs, soy, nuts, fish, shellfish, sesame) as well as ultra-processed foods, artificial sweeteners, food dyes, additives, and environmental toxins that may impair gut integrity and provoke immune activation. The second step, replace, emphasizes supporting digestion and absorption by replenishing deficient digestive enzymes, bile acids, or hydrochloric acid when clinically indicated, while also addressing key micronutrient deficiencies, particularly vitamin D and iron. The third component, reinoculate, aims to restore microbial balance by introducing probiotics, prebiotics, and fermented foods such as yogurt, kefir, sauerkraut, and kimchi, all of which have been linked to improved gastrointestinal and immune health in children with autoimmune conditions. The fourth step, repair, focuses on strengthening the gut barrier with nutrients such as L-glutamine, zinc carnosine, and omega-3 fatty acids, thereby enhancing mucosal healing and reducing intestinal permeability. Finally, rebalancing incorporates long-term, sustainable dietary and lifestyle measures, including adherence to an anti-inflammatory diet, stress management, adequate sleep, outdoor activity, and regular physical exercise, all of which help maintain gut and immune homeostasis[52-54]. For children with celiac disease, strict adherence to a gluten-free diet is mandatory. Still, gluten avoidance may also be considered in other autoimmune conditions, given the potential role of gliadin in upregulating zonulin and disrupting intestinal barrier integrity. However, such strategies should be carefully individualized and guided by clinical expertise to avoid un
Practical implementation remains a challenge in pediatric care, as restrictive diets can be socially isolating and difficult to maintain. Family-centered approaches, in which parents and siblings adopt similar dietary practices, may enhance adherence and reduce stigma[56,57]. Actively involving children in meal planning, grocery shopping, and cooking has been shown to increase engagement, autonomy, and long-term adherence to anti-inflammatory eating patterns. Strategies such as modeling healthy behaviors, creating routine family meals, encouraging nutrient-dense snacks, replacing sweetened beverages with water, and minimizing reliance on restaurant or processed foods can help integrate anti-inflammatory nutrition into daily life[58]. Despite logistical and behavioral challenges, evidence supports a strong link among diet, gut health, and immune outcomes in children at risk of autoimmunity. By combining nutrient sufficiency, microbial support, and reducing pro-inflammatory dietary exposures, nutritional interventions represent a powerful, modifiable strategy for delaying or preventing the onset of autoimmune diseases in high-risk pediatric populations[39].
The human microbiome, particularly the gut microbiota, a complex ecosystem of trillions of microorganisms, plays a critical role in shaping immune development and maintaining immune tolerance, thereby influencing susceptibility to autoimmune diseases[59]. According to the “Old Friends Hypothesis”, early-life exposure to diverse and beneficial microbes, many of which have co-evolved with humans for millennia, is essential for training the immune system to distinguish between harmful pathogens and harmless antigens[60]. This educational process occurs during a highly sensitive “window of opportunity” known as the first 1000 days (from conception to age two). As illustrated in Figure 1, this period follows a precise temporal sequence in which maternal health, delivery mode, and early feeding patterns dictate the trajectories of both microbial colonization and immune maturation.
The presence of a rich and diverse microbiome during critical developmental windows, particularly in the first few years of life, is essential for a balanced and mature immune system capable of distinguishing self from non-self[61]. Reduced microbial exposure due to modern lifestyles - characterized by increased hygiene, cesarean deliveries, limited breastfeeding, and urban living - has been implicated in failure to properly “educate” the immune system and the rising incidence of autoimmune and allergic diseases in children. This lack of early microbial interaction may impair regulatory T-cell development and lead to exaggerated immune responses later in life[62].
Another key aspect of microbiome-immune interaction is the cautious use of antibiotics in childhood. While antibiotics are lifesaving when clinically indicated, unnecessary or repeated prescriptions can disrupt gut microbial diversity, leading to long-term consequences for immune regulation[63]. A large body of evidence from both animal models and human cohort studies has demonstrated that antibiotic use, especially in infancy and early childhood, is associated with a higher risk of developing autoimmune conditions like IBD and T1DM[35]. For instance, studies have shown a dose-dependent relationship between early antibiotic exposure and increased risk of IBD, with some evidence suggesting that broad-spectrum antibiotics are particularly disruptive. This is because antibiotics can indiscriminately kill beneficial bacteria, leading to a loss of microbial diversity and a shift towards pro-inflammatory microbial profiles. Such dysbiosis can alter the production of key metabolites, such as short-chain fatty acids like butyrate, which are crucial for maintaining gut barrier integrity and promoting a tolerant immune response[64,65]. This disruption represents a significant “window of vulnerability” in the developmental roadmap, where the loss of microbial signaling can serve as the environmental spark for preclinical autoimmunity, increasing the risk of conditions such as T1DM, IBD, and asthma. Therefore, stewardship in antibiotic prescribing, ensuring their use only when necessary, is a cornerstone in preserving microbiome health and preventing immune dysregulation in high-risk children[66].
Beyond avoiding harm, targeted microbiome modulation strategies are emerging as promising avenues for auto
Similarly, prebiotics - non-digestible dietary fibers that selectively promote beneficial bacteria - exert immunomodulatory effects through short-chain fatty acid production, which enhances regulatory T-cell expansion and anti-inflammatory pathways. Current data suggest that the efficacy of both probiotics and prebiotics depends on selecting the right strain, dose, and timing, reinforcing the importance of precision approaches[69]. A “one-size-fits-all” strategy is unlikely to succeed; instead, future interventions will likely require personalization based on genetic background and baseline microbiome composition. Taken together, the preservation and strategic modulation of the microbiome hold significant promise for preventing the onset of autoimmune disease in genetically predisposed individuals[70]. By combining principles of judicious antibiotic use with proactive microbiome-targeted interventions, clinicians may reduce au
Environmental factors play a critical role in the onset and progression of autoimmune diseases, often interacting with genetic susceptibility to disrupt immune tolerance. Strategies to reduce or eliminate modifiable environmental triggers are therefore central to primary prevention in high-risk children (Table 2)[71]. Tobacco smoke exposure, both direct and secondhand, has been consistently associated with immune dysregulation and heightened risk of autoimmune con
| Environmental trigger | Associated autoimmune risk | Proposed mechanism | Prevention strategy |
| Tobacco smoke | JIA, T1DM, multiple sclerosis, rheumatoid arthritis, SLE | Induces oxidative stress, promotes pro-inflammatory cytokines, impairs T-cell function, and alters epigenetic markers | Complete avoidance of prenatal and second-hand smoke exposure |
| Endocrine disruptors (e.g., BPA, phthalates, pesticides) | Increased autoantibody production, immune dysregulation | Mimic or block hormones critical for immune regulation; can alter gut microbiome and promote inflammation | Use glass/stainless steel containers, avoid microwaving in plastic, buy organic produce, and use non-toxic household products |
| Infections (viruses and bacteria) | T1DM (enteroviruses), lupus (EBV), myocarditis (coxsackievirus) | Molecular mimicry (pathogen antigens resemble self-antigens), bystander activation (inflammation damages tissues and releases self-antigens) | Adhere to vaccination schedules for preventable diseases |
| Nutrient deficiencies (vitamin D) | T1DM, SLE, multiple sclerosis, rheumatoid arthritis | Impairs regulatory T-cell function and promotes pro-inflammatory Th1 and Th17 pathways | Ensure adequate vitamin D intake through sunlight exposure, fortified foods, or supplementation as recommended by a physician |
| Diet (high sugar/fat, low fiber) | IBD, T1DM, rheumatoid arthritis | Promotes gut dysbiosis, “leaky gut” (increased intestinal permeability), and systemic inflammation | Emphasize a diet rich in fiber, fruits, vegetables, and whole grains; limit processed foods, sugar, and unhealthy fats |
| Stress (physical/psychological) | IBD, psoriasis, rheumatoid arthritis, SLE | Activates the hypothalamic-pituitary-adrenal axis, leading to the release of stress hormones (e.g., cortisol) and pro-inflammatory cytokines that can exacerbate autoimmunity | Promote stress-reduction techniques such as mindfulness, adequate sleep, and physical activity |
| Overly sterile environment | Impaired immune tolerance (hygiene hypothesis) | Lack of exposure to diverse microbes and parasites in early life impairs the maturation of regulatory T-cells and other immune-modulating pathways | Encourage balanced microbial exposure through outdoor play, pets, and safe interaction with natural environments |
Endocrine-disrupting chemicals, such as BPA, phthalates, and organophosphate pesticides, have raised increasing concern due to their immunotoxic and hormone-mimicking properties. Early-life exposure to these compounds has been linked to immune imbalance, increased autoantibody production, and a heightened risk of autoimmunity[74]. Practical avoidance strategies include limiting the use of BPA-containing plastics, avoiding microwaving food in plastic containers, choosing glass or stainless-steel alternatives, and prioritizing fresh or organic produce to minimize pesticide exposure. Although the complete elimination of endocrine-disrupting chemicals is unrealistic in modern environments, awareness of and reduction of high-exposure sources can significantly mitigate risk[75,76].
Infection control represents another crucial area of preventive focus. While certain infections can act as immune triggers that precipitate autoimmune processes, controlled exposure to microbes is essential for healthy immune maturation. Vaccination adherence provides a safe and effective means of protecting children against infections that exacerbate autoimmune susceptibility, such as enteroviruses in T1DM[77,78]. On the same hand, the “hygiene hy
Secondary prevention of autoimmune diseases focuses on early detection in asymptomatic but high-risk children to identify disease-specific immune activity before clinical manifestations occur. The cornerstone of this approach is periodic screening using autoantibody panels, tailored to the child’s genetic susceptibility and family history (Table 3)[83]. This predictive strategy enables clinicians to identify children most likely to progress toward clinical disease and implement early interventions. For genetically predisposed children - such as those with a first-degree relative diagnosed with an autoimmune disorder or who carry high-risk HLA genotypes - regular blood testing can reveal the presence of disease-related autoantibodies years before symptoms appear. This process of identifying subclinical autoimmunity represents a pivotal shift from a reactive, symptomatic diagnostic model to a proactive disease-interception strategy[84,85]. However, it is essential to acknowledge a significant disparity in the quality of clinical evidence and the degree of protocol standardization across different conditions. While screening for T1DM and celiac disease is supported by robust longitudinal data, screening for other conditions such as SLE and JIA remains less standardized and often exploratory.
| Autoimmune disease | High-risk population | Key antibodies for screening | Interpretation | Potential early intervention |
| Established standard | ||||
| T1DM | Children with a first-degree relative with T1DM or high-risk HLA genotypes | GAD65, IA-2, insulin autoantibodies, ZnT8 | High evidence quality: ≥ 2 positive antibodies = high risk of progression to diabetes | Close monitoring, enrollment in prevention trials (e.g., teplizumab for stage 2), lifestyle/dietary counseling |
| Celiac disease | Children with a first-degree relative with celiac disease, or high-risk HLA (DQ2/DQ8) | Anti-tTG (IgA), EMA, deamidated gliadin peptide antibodies | High evidence quality: Positive serology suggests a high likelihood of disease and villous atrophy even in asymptomatic children | Early dietary intervention (gluten-free diet) to prevent growth failure and nutritional deficiencies |
| Autoimmune thyroid disease | Children with a family history of thyroid disease, or other autoimmune disorders (e.g., T1DM, down syndrome, turner syndrome) | Anti-thyroid peroxidase, anti-thyroglobulin | Moderate-high evidence quality: Antibody positivity often precedes clinical hypothyroidism/thyroiditis | Monitoring thyroid function, early initiation of hormone therapy if indicated |
| Emerging/research | ||||
| SLE (research/experimental use) | Offspring of mothers with SLE or anti-Ro/SSA positivity | ANA, anti-dsDNA, anti-Ro/SSA. Antibodies may appear before clinical disease | Lower specificity: ANA is highly sensitive but lacks specificity for prediction in asymptomatic children | Serial monitoring; counseling on sun protection and infection triggers; hydroxychloroquine in specific research cohorts |
| JIA | Children with a strong family history of JIA or early-onset uveitis | ANA, RF, anti-CCP, HLA-B27 | Lower evidence quality: ANA is primarily a marker for uveitis risk; RF/anti-CCP are predictive of severe polyarticular course but not disease onset | Baseline ophthalmologic exam for uveitis; prompt referral upon subtle musculoskeletal symptoms |
The best-established examples of a successful secondary prevention strategy is screening children at risk of T1DM and celiac disease. Screening for T1DM involves testing for a panel of islet autoantibodies, including GAD65, IA-2, insulin autoantibodies, and zinc transporter 8 antibodies. The detection of two or more autoantibodies strongly correlates with a high lifetime risk of developing diabetes, often preceding the onset of hyperglycemia by several years[86]. For instance, the presence of these antibodies signifies a progression from the initial “at-risk” stage to a more advanced stage of subclinical autoimmunity. Early identification opens opportunities for close monitoring, participation in clinical trials for new preventive therapies (e.g., immunomodulatory drugs), and timely clinical intervention to manage the transition from subclinical autoimmunity to overt disease.
High-risk individuals for celiac disease, such as children with a first-degree relative with celiac disease or those with HLA-DQ2/DQ8 genotypes, may benefit from periodic screening with serological markers. The primary markers are anti-tTG antibodies and, in some cases, anti-endomysial antibodies. Detecting these antibodies early enables timely dietary modifications, such as adopting a gluten-free diet, which can prevent irreversible intestinal damage and nutrient malabsorption, and reduce the risk of long-term complications[87,88]. This proactive intervention halts the autoimmune process triggered by gluten ingestion, protecting the gut and overall health.
The value of targeted screening extends beyond T1DM and celiac disease. Screening for other autoimmune conditions, such as autoimmune thyroid disease and SLE, is also being explored. In autoimmune thyroid disease, screening for anti-thyroid peroxidase (TPO) and anti-thyroglobulin antibodies in at-risk children (e.g., those with T1DM or family history) can detect early thyroid dysfunction[89]. While ANA are highly sensitive markers that often precede clinical SLE by years, they lack the high specificity of T1DM markers. Current recommendations focus on high-risk individuals, such as offspring of mothers with anti-Ro/Sjögren syndrome-related antigen A antibodies, using a panel of ANA, anti-dsDNA, and anti-Sm. In these cases, longitudinal monitoring of ANA, anti-dsDNA, and anti-Sm is used to track the “immunological signature” of disease evolution, though universal screening intervals are not yet standardized[90]. In JIA, predictive screening is currently less standardized than for T1DM. ANA positivity is a critical marker for stratifying uveitis risk in children with established JIA, but has limited specificity as a lone predictive tool for disease onset in asymptomatic children. For those with a strong family history, monitoring for rheumatoid factor and anti-cyclic citrullinated peptide is recommended only when subtle clinical signs emerge, emphasizing the need for clinician vigilance rather than routine laboratory screening in asymptomatic cohorts[18,43,72].
It is important to note that screening is not recommended for the general pediatric population but is highly effective when targeted to children with established risk factors. This approach, while promising, also poses challenges, including the psychological burden on families of knowing their child is at risk and the need for standardized screening protocols[91]. However, by enabling earlier dietary, lifestyle, or pharmacological interventions, periodic antibody screening is a pivotal tool in secondary prevention, offering a clear pathway toward a future in which autoimmune diseases can be intercepted and managed before they cause significant clinical harm.
Following the identification of high-risk children through screening, surveillance becomes the next critical step in secondary prevention. It aims to identify early physiological changes in asymptomatic, high-risk children that may signal the onset of autoimmune disease before clinical manifestations occur. This involves systematic and ongoing monitoring for the earliest signs of immune dysregulation or disease progression, even before classic clinical symptoms appear. Unlike one-time screening, surveillance is a continuous process that allows clinicians to track a child’s health trajectory and intervene at the optimal moment. Regular monitoring allows for early intervention, potentially mitigating disease progression and preventing long-term complications.
For children identified as high-risk for T1DM through antibody screening, surveillance includes regular monitoring of blood glucose and hemoglobin A1c levels. This enables early detection of subtle changes, such as impaired glucose tolerance, which signal progression from subclinical autoimmunity to symptomatic disease. Timely detection of these changes allows rapid intervention to prevent diabetic ketoacidosis, a life-threatening complication at the time of diagnosis[92].
For autoimmune thyroid disease, periodic thyroid function monitoring is recommended for children at elevated risk, particularly those with a family history of thyroid autoimmunity, T1DM, or other autoimmune disorders. Screening typically involves measuring serum thyroid-stimulating hormone and free thyroxine levels, supplemented by testing for TPO or thyroglobulin autoantibodies when indicated. This approach can identify subclinical hypothyroidism or hyperthyroidism, allowing for prompt initiation of treatment, reducing risks of impaired growth, neurocognitive effects, and metabolic complications[93,94].
Growth tracking is a valuable, non-invasive surveillance tool for several pediatric autoimmune conditions. For children at risk for celiac disease or IBD, a decline in growth velocity or a sudden drop in weight-for-height percentile can be an early indicator of disease activity. This is due to nutrient malabsorption or chronic inflammation, which can affect a child’s ability to thrive[95,96]. Similarly, growth tracking can be a simple yet effective component of surveillance for other chronic conditions, such as JIA[97].
Overall, surveillance is a dynamic and personalized process that complements targeted screening. It shifts the focus from a single data point to a continuous health profile, allowing clinicians to make informed decisions and initiate interventions that can alter the course of autoimmune disease, improve long-term outcomes, and prevent serious complications[98].
When early screening or surveillance reveals autoimmune-related biomarkers or subclinical abnormalities in genetically predisposed but asymptomatic children, lifestyle optimization emerges as a critical secondary preventive measure. These strategies aim to modulate the immune system and reduce the risk of progression to overt autoimmune disease by addressing modifiable environmental and nutritional factors that influence immune homeostasis[99]. Figure 10 shows a clinical decision-support algorithm for lifestyle optimization in children at high risk of autoimmune disease.
Dietary adjustments play a foundational role, particularly in conditions such as celiac disease or T1DM. For children with early signs of celiac disease autoimmunity, implementing a gluten-free diet can prevent the inflammatory cascade that leads to intestinal damage[100]. Similarly, for other autoimmune conditions such as T1DM and IBD, adopting a diet that reduces processed foods, refined sugars, and unhealthy fats while emphasizing whole foods, fruits, and vegetables, lean proteins, and omega-3 fatty acids can help reduce systemic inflammation and support a healthy gut microbiome[101,102].
Vitamin D correction is another critical intervention, given the strong association between vitamin D deficiency and autoimmunity. Low vitamin D levels are common in children at risk of autoimmunity and are associated with a pro-inflammatory immune state[103]. Regular monitoring of serum 25-hydroxyvitamin D levels and correction of any deficiency through supplementation is a simple yet powerful strategy to support regulatory T-cell function, preserve immune tolerance, and reduce the likelihood of disease onset. Clinical trials have shown that adequate vitamin D levels may help reduce the risk of T1DM progression in high-risk individuals[104].
Furthermore, microbiome support plays a key role in lifestyle optimization, as gut dysbiosis is implicated in multiple autoimmune diseases. Beyond dietary fiber, targeted use of probiotics and prebiotics can help restore and maintain a healthy gut microbiota, promote a healthy microbial ecosystem, improve gut barrier integrity, and balance immune activity[9]. For example, specific probiotic strains have been shown to improve gut barrier function and reduce inflammation in some studies. This approach, though still evolving, aims to directly address gut dysbiosis, which often precedes the onset of autoimmune disease[105]. Moreover, interventions such as breastfeeding promotion in infancy and cautious antibiotic use during childhood support the long-term development of a resilient microbiota[106].
Other strategies include promoting stress management, ensuring adequate age-appropriate physical activity, and optimizing sleep quality, all of which have been shown to influence immune function. By combining these lifestyle interventions, clinicians and families can create an environment that promotes immune balance and resilience, potentially delaying or even preventing progression to full-blown autoimmune disease in genetically susceptible children[107]. By integrating lifestyle optimization into secondary prevention frameworks, clinicians and families may have the opportunity to intervene at a pivotal stage - potentially delaying or even preventing the clinical onset of autoimmune diseases[108].
The ultimate goal of secondary prevention is not just to detect autoimmune disease early, but to stop its progression. This is the purpose of targeted clinical trials investigating pre-symptomatic immunomodulation and intervening before the clinical onset of disease, thereby delaying or even preventing the transition from subclinical autoimmunity to overt autoimmune pathology. These trials enroll high-risk, asymptomatic children - identified through screening and sur
Several clinical trials are currently exploring whether immune tolerance can be induced in children who carry high-risk genotypes or who already show early serological evidence of autoimmunity (such as autoantibodies). The most notable success in this area is the use of teplizumab, a monoclonal antibody targeting the CD3 epsilon chain of the T-cell receptor complex. Unlike broad immunosuppressants, teplizumab acts as a partial T-cell receptor agonist that modulates the immune environment without systemic depletion[110,111]. As detailed in Figure 11, teplizumab induces a state of functional “exhaustion” or anergy in autoreactive CD8+ effector T cells, characterized by the upregulation of inhibitory markers such as programmed cell death protein 1 and T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domain. Simultaneously, it appears to shift the broader immune regulatory network toward tolerance by promoting the expansion or preservation of regulatory T cells. This targeted modulation dampens the cytotoxic inflammatory attack on pancreatic islets, effectively preserving residual beta-cell mass and endogenous insulin production. Clinical trials have shown that a single 14-day course of teplizumab in high-risk individuals with stage 2 T1DM (multiple autoantibodies and abnormal glucose tolerance) can significantly delay the onset of clinical diabetes by a median of about two to three years. This ground-breaking finding led to teplizumab’s approval as the first drug to delay the progression of an autoimmune disease. This success validates the entire secondary prevention approach, demonstrating that in
Another promising avenue has been oral or intranasal insulin trials. The idea is to expose the immune system to insulin orally or nasally in a controlled, non-inflammatory manner, in hopes of inducing immune tolerance to the very protein it mistakenly attacks and reducing autoreactive T-cell responses[112,113]. While early trials did not show a significant effect in the overall population, a subgroup analysis revealed that oral insulin might delay the onset of T1DM in children with high insulin autoantibody levels[114]. This finding highlights the importance of a more personalized, or “precision medicine”, approach: Tailoring interventions to immunological profiles and targeting specific subgroups of at-risk individuals, which may be more effective.
Similar immunomodulatory strategies are being tested for coeliac disease by examining the optimal timing of gluten introduction and by using controlled antigen-exposure studies[115]. In addition, trials of low-dose immunomodulators or micronutrient supplementation (e.g., selenium) were conducted to slow the progression of autoimmune thyroiditis[116]. Similarly, early B-cell-targeted therapies were tried in high-risk children with multiple sclerosis with positive radiological or serological markers[117].
These trials represent a paradigm shift in the treatment of autoimmune diseases. Instead of waiting for symptoms and managing the disease, the focus is on a proactive, interventional approach to prevent it from ever fully manifesting. While these therapies are not yet widespread, they are paving the way for a future in which autoimmune diseases may be preventable rather than just manageable. However, conducting such trials in children raises critical ethical challenges. Since these individuals are asymptomatic, the risk-benefit balance must be carefully evaluated. Long-term safety, parental consent, and psychosocial implications of labeling a child “pre-symptomatic” require thoughtful navigation. Moreover, sustained follow-up and international collaboration are essential to generate robust evidence.
Once an autoimmune disease is clinically established, tertiary prevention strategies become essential to limit long-term complications, prevent irreversible organ damage, and preserve organ function. Early, aggressive therapy is a cornerstone of this approach, aiming not only to control disease symptoms before they cause significant and lasting harm, but also to halt or slow disease progression at the earliest stages[118]. The rationale is that irreversible organ damage often occurs before the disease reaches its chronic phase; therefore, the initial period of an autoimmune disease is a critical window of opportunity in which the inflammatory process can be most effectively halted, and timely intervention can profoundly alter the natural course of illness[119].
Disease-modifying therapies, such as biologics and targeted immunomodulators, have transformed the management of conditions like T1DM, JIA, and pediatric IBD. These agents specifically target immune pathways, thereby reducing chronic inflammation and preventing cumulative tissue injury[120]. In conditions like JIA, delaying effective treatment can lead to permanent joint destruction, pain, and disability. The standard of care has shifted from a “step-up” approach to a “treat-to-target” strategy, in which the goal is to achieve and maintain remission. This often involves the prompt use of disease-modifying antirheumatic drugs, such as methotrexate, and, increasingly, biologic therapies that target specific inflammatory cytokines, such as tumor necrosis factor inhibitors[121,122]. When initiated early, these treatments can suppress inflammation, prevent the progression of joint damage, reduce disability in children, and improve growth outcomes.
Similarly, in SLE, early and aggressive therapy is crucial to prevent multi-organ involvement, particularly kidney damage (lupus nephritis). Treatment typically begins with corticosteroids and is often combined with other immunosuppressants, such as mycophenolate mofetil or cyclophosphamide. The goal is not just to manage symptoms but to directly suppress the autoimmune response to protect vital organs[123,124]. Additionally, in pediatric T1DM, immunotherapeutic strategies under investigation aim to preserve residual β-cell function, thereby reducing the long-term burden of microvascular and macrovascular complications[125].
Beyond pharmacological interventions, multidisciplinary therapeutic measures are equally vital. Structured physiotherapy and occupational therapy in autoimmune rheumatic diseases support musculoskeletal health and functional independence[126]. Nutritional optimization - ensuring adequate vitamin D, calcium, and micronutrients - can mitigate the risk of osteoporosis and other systemic complications[127]. Moreover, tight monitoring of comorbidities, such as cardiovascular risk in SLE, enables integrated care that addresses both immediate and long-term threats[128].
Overall, early aggressive therapy in tertiary prevention underscores the importance of prompt recognition, swift initiation of disease-modifying treatment, and holistic patient care. This proactive approach underscores a fundamental shift in the management of autoimmune disease and can significantly reduce the disease burden[129]. Instead of waiting for complications to arise, clinicians now work to pre-emptively shut down the destructive immune attack, thereby preserving organ function, improving the long-term quality of life for children with these chronic conditions, and improving their survival outcomes.
Education and empowerment are cornerstones of tertiary prevention in children with established autoimmune diseases. Beyond pharmacological treatment, equipping patients and their families with the knowledge and skills needed for effective long-term disease management fosters better disease management, adherence, and quality of life[130]. Family-centered disease management recognizes that children depend heavily on caregivers for treatment adherence, lifestyle choices, and emotional support. This approach moves beyond passive treatment by clinicians to an active partnership in care[131].
A core element is the development of a family-centered disease management plan. This plan is not a one-size-fits-all approach but is tailored to the child’s specific needs, lifestyle, and developmental stage. Structured educational programs help families understand the natural history of autoimmune diseases, potential complications, and the importance of timely interventions[132]. Such programs often include training on medication use and possible side effects, recognizing symptoms and early signs of disease flares, maintaining appropriate nutrition, infection prevention strategies, and crisis management. The goal is to demystify the disease and its treatment, helping families feel more in control and less overwhelmed[133]. For conditions such as T1DM, teaching parents and children how to monitor blood glucose, count carbohydrates, and administer insulin is essential[134]. For a child with JIA, education would focus on the importance of medication adherence, the role of physical therapy, and strategies for managing pain and joint stiffness[135]. Similarly, in autoimmune thyroiditis or celiac disease, guidance on hormone monitoring and strict dietary adherence is critical[136].
Empowerment strategies go beyond education by encouraging active participation in care planning and shared decision-making. It involves fostering the child’s self-advocacy as they grow. As children become adolescents, they are encouraged to take on a greater role in their own care, from tracking their symptoms to communicating with their healthcare team[137]. This transition is essential to ensuring long-term treatment adherence and a smoother transition to adult care. This can be achieved by setting realistic goals for disease management, adapting school and social activities to the child’s health needs, and ensuring psychosocial support to minimize stigma and improve resilience. Digital tools such as mobile applications, telemedicine consultations, and online peer-support groups further enhance empowerment by providing accessible resources and fostering a sense of community[138].
Ultimately, family-centered approaches improve adherence, reduce complications, and promote a holistic model of care. By involving the entire family unit, these strategies not only safeguard the child’s immediate health but also lay the foundation for long-term self-management and independence as the child transitions into adulthood[139]. By prioritizing education and empowerment, tertiary prevention aims to reduce disease-related anxiety, improve quality of life, and decrease the risk of long-term complications that often arise from poor disease control[140].
Children with established autoimmune diseases are at heightened risk of developing comorbidities that may significantly impact long-term health outcomes. In addition, chronic inflammation and long-term use of certain medications can increase the risk of other health issues[141]. Therefore, tertiary prevention for established autoimmune diseases also includes proactive strategies to prevent and manage associated comorbidities. A comprehensive management plan must address these potential complications through a multidisciplinary approach to care[142].
One of the most critical considerations is cardiovascular risk reduction, particularly in children with SLE and T1DM. Both conditions are associated with chronic inflammation, dyslipidemia, endothelial dysfunction, and increased oxidative stress, which collectively predispose affected children to premature atherosclerosis and significantly increase the risk of heart disease, often at a much younger age than in the general population[143]. In SLE, this is due to chronic inflammation, which accelerates atherosclerosis. In T1DM, it is a direct consequence of prolonged hyperglycemia and associated metabolic changes. Comorbidity prevention in these cases involves aggressive management of traditional cardiovascular risk factors, including regular lipid profile screening, blood pressure monitoring, and strict blood glucose monitoring[144]. For children and adolescents with these conditions, this may mean early and consistent monitoring, dietary interventions, and lifestyle modifications, emphasizing a healthy diet, exercise, and avoidance of smoking exposure to maintain a healthy weight and activity level. When indicated, pharmacologic interventions, such as statins or antihypertensives, may be warranted to further reduce long-term cardiovascular morbidity[145,146].
Another critical area is bone health monitoring, particularly for children on long-term steroid therapy for autoimmune conditions. While corticosteroids are highly effective in controlling inflammation in diseases such as JIA and lupus nephritis, their prolonged use can reduce bone mineral density, increasing the risk of osteoporosis and fractures. Prevention strategies include ensuring adequate calcium and vitamin D intake, regular weight-bearing exercise, and baseline and periodic bone density scans (e.g., dual-energy X-ray absorptiometry) to detect early signs of bone loss. In some cases, medication to protect bone density, such as bisphosphonate therapy, may be considered[5,147].
Additionally, comorbidity prevention should extend to metabolic monitoring (e.g., obesity and insulin resistance in patients on chronic immunosuppressants), infection surveillance (due to immunosuppression), and mental health support to address the psychological burden of chronic disease. These measures not only prevent secondary complications but also preserve growth, development, and quality of life in affected children[148]. By proactively addressing these and other comorbidities, tertiary prevention aims to improve not only the short-term symptoms of the autoimmune disease but also the child’s long-term health and well-being, ensuring the best possible outcomes as they transition into adulthood and ultimately reducing the cumulative burden of autoimmune diseases.
Psychosocial support is a critical but often underemphasized component of tertiary prevention in children with established autoimmune diseases. Beyond the physical burden of chronic illness, these children frequently encounter significant emotional and social challenges[149]. Regular hospital visits, invasive treatments, long-term medication use, and the unpredictability of disease flares can contribute to anxiety, depression, social withdrawal, and diminished self-esteem. For example, children with JIA may experience chronic pain and limited mobility that hinder participation in sports or social activities[150]. At the same time, those with T1DM face the ongoing stress of blood glucose monitoring and dietary vigilance - burdens that can feel isolating during adolescence. Similarly, SLE often brings periods of intense fatigue and visible side effects of therapy, adding to the psychological toll[151].
Early recognition and proactive management of these psychosocial concerns are essential, as mental well-being strongly influences treatment adherence, disease control, and long-term quality of life. Effective strategies include routine mental health screening and integrating psychologists, social workers, and school counselors into multidisciplinary care teams[152]. Targeted interventions may involve individual counseling to help children develop coping strategies and maintain self-esteem, family therapy to strengthen communication and reduce caregiver stress, and peer support groups to foster a sense of belonging through shared experiences. School-based support is equally important, ensuring acco
In addition, resilience-building measures - such as cognitive behavioral therapy, mindfulness training, and structured stress-reduction programs - can equip children and families with lifelong tools to manage the unpredictability of chronic illness. Supporting parents and caregivers through education and counseling is equally vital, as caregiver well-being directly affects the child’s emotional adaptation[154]. Ultimately, addressing psychosocial health is not an optional adjunct but a cornerstone of tertiary prevention. By prioritizing mental health and resilience alongside medical treatment, healthcare providers can improve adherence, reduce disease-related distress, and enable children with autoimmune conditions to achieve their full developmental potential and a better quality of life[155].
Identifying a child as high-risk can trigger significant parental anxiety, particularly in mothers, and may lead to persistent worry about the unpredictability of disease onset. To mitigate these effects, clinical programs should im
One of the foremost challenges in the implementation of effective strategies for the early prevention and management of autoimmune diseases in high-risk children lies in the predictive limitations of genetic and antibody testing. While these diagnostic tools have advanced considerably in recent years, their clinical utility is not without significant constraints[10,159].
From a genetic standpoint, the identification of susceptibility loci, such as HLA haplotypes (e.g., HLA-DR3, HLA-DR4, HLA-DQ8), has dramatically enhanced our understanding of the heritable risk associated with autoimmune conditions, particularly T1DM, celiac disease, and autoimmune thyroiditis[160]. However, the presence of these alleles alone is not sufficient to reliably predict disease onset. Many individuals carrying these risk alleles remain healthy throughout their lifetime, underscoring the incomplete penetrance of genetic markers. This limitation is particularly evident in the polygenic nature of most autoimmune diseases, where multiple genetic variants of small effect interact in complex, often unpredictable ways with environmental exposures to drive disease expression[161]. Thus, while genetic testing can stratify individuals into higher- or lower-risk categories, it lacks the precision needed to determine who will ultimately progress to clinical disease and when.
Similarly, antibody-based screening, such as testing for islet autoantibodies (insulin autoantibodies, GAD65, IA-2, zinc transporter 8) in T1DM or for anti-TPO and anti-thyroglobulin antibodies in autoimmune thyroid disease, provides valuable insights into ongoing subclinical immune activity[162]. The detection of multiple autoantibodies, especially in young children, correlates strongly with an increased likelihood of progression to overt autoimmune disease[163]. Yet, antibody positivity is not synonymous with inevitable disease development. Some children may harbor autoantibodies for many years without ever transitioning to symptomatic disease, while others may progress rapidly within months of detection. This variability introduces considerable uncertainty, complicating the interpretation of results for both clinicians and families[164].
Another limitation is the dynamic nature of autoimmunity, where serological markers may appear and disappear over time. A child initially testing negative for autoantibodies may later develop them, and conversely, transient antibody positivity may not always lead to sustained autoimmunity. This instability poses challenges in establishing reliable screening intervals and highlights the inadequacy of a single test to capture the evolving trajectory of immune dysregulation[165,166].
The predictive shortcomings of both genetic and antibody testing also raise practical and ethical dilemmas. On the practical side, widespread population-based screening using these markers may result in a high number of false positives or inconclusive results, generating anxiety for families and unnecessary healthcare utilization[167]. Ethically, disclosing a child’s elevated risk of developing a potentially serious autoimmune condition - without the ability to offer a guaranteed preventive or curative intervention - may lead to psychological distress, stigma, and altered family dynamics. Parents may struggle with uncertainty, while children may internalize a sense of vulnerability long before disease onset[168].
Furthermore, the interpretation of predictive testing is highly context-dependent. Genetic and antibody markers may have varying predictive values depending on ethnicity, family history, and environmental exposures. What may be considered a strong predictor in one population may not carry the same weight in another, thereby limiting the generalizability of findings and necessitating region-specific validation of predictive algorithms[169].
In sum, while genetic and antibody testing represent essential tools for identifying children at increased risk of autoimmune disease, their limitations in sensitivity, specificity, temporal accuracy, and ethical implications remain significant barriers. These challenges underscore the need for more integrative predictive models that combine genetic, immunological, metabolic, microbiome, and environmental data to enhance precision. Until such advances are realized, reliance on current predictive tools must be tempered with caution, clear communication, and a holistic approach to counseling families about both the potential and the limitations of these tests.
One of the most significant challenges in the early identification and prevention of autoimmune diseases lies in the ethical considerations surrounding the labeling of children as “high-risk”[170]. Advances in genetic and immunologic testing have enabled the identification of children who carry susceptibility alleles or autoantibody profiles that increase their risk of developing autoimmune conditions such as T1DM, celiac disease, or SLE. While this knowledge holds tremendous potential to guide preventive strategies, it also raises profound ethical dilemmas regarding autonomy, stigmatization, psychological burden, and medical decision-making in a vulnerable population[171,172].
The labeling of asymptomatic children as “high-risk” must be grounded in established ethical frameworks, such as those provided by the American Academy of Pediatrics and the American College of Medical Genetics and Genomics. These organizations emphasize that the “best interest of the child” must be the primary consideration in any screening or testing program[173]. Current guidelines generally discourage predictive testing for adult-onset conditions to preserve the child’s right to decide for themselves upon reaching maturity[174]. However, for childhood-onset conditions like T1DM or celiac disease, testing is ethically permissible - and often recommended - if early identification leads to tangible clinical benefits, such as the prevention of diabetic ketoacidosis or growth failure[175]. Organizations like the International Society for Pediatric and Adolescent Diabetes provide rigorous clinical frameworks for monitoring children who test positive for autoantibodies (e.g., repeating tests in independent labs and structured metabolic monitoring), ensuring that the “high-risk” label translates into high-quality care rather than just psychological burden[176]. Ethical protocols must also respect parental rights to refuse screening after being fully informed of the benefits and risks, a principle upheld in international bioethics recommendations.
A primary concern is the potential psychological impact on both children and their families. Being labeled as “high-risk” can cause anticipatory anxiety, fear, and even feelings of helplessness, particularly when no definitive preventive intervention is yet available. For children, this label may influence self-identity and create an unnecessary sense of being “ill” despite being asymptomatic. For parents, it may foster overprotectiveness, guilt, or decisional conflict regarding interventions, surveillance, or lifestyle modifications. Such unintended psychosocial consequences can compromise overall well-being and quality of life, thereby negating some of the benefits of early risk identification[177].
Stigmatization and discrimination represent another ethical dimension. Knowledge of a child’s predisposition to autoimmune disease may inadvertently lead to differential treatment in educational, social, or even insurance contexts. Concerns exist that disclosure of genetic or immunologic risk information could affect insurability or lead to unfair categorization, particularly in societies with underdeveloped genetic privacy protections. These risks underscore the need for robust safeguards regarding confidentiality and data use[178].
Another layer of complexity lies in the ethical principle of autonomy. Children, by definition, lack full decision-making capacity, and the responsibility falls to parents or guardians to consent to genetic or autoantibody testing and subsequent preventive interventions. However, this creates tension between parental authority and the child’s evolving capacity for assent and future autonomy[179]. For example, a child may grow up resenting decisions made on their behalf regarding testing or interventions based on risk rather than certainty[180]. This raises critical questions about timing: Should testing be deferred until the child can participate in the decision, or should it be pursued early to maximize preventive opportunities?
Moreover, the principle of beneficence - acting in the best interest of the child - must be weighed against non-maleficence, the obligation to avoid harm. Without adequate, widely accepted preventive measures, labeling a child as high-risk may do more harm than good[180]. It can create a situation where families live with knowledge of a looming health risk but lack actionable steps to prevent disease onset. This dilemma highlights the ethical importance of linking predictive testing to meaningful clinical pathways, rather than offering risk information in isolation[181]. Finally, equity considerations must not be overlooked. Access to predictive testing and subsequent monitoring is not uniformly available, especially in low- and middle-income settings. Ethical concerns arise when only specific populations benefit from early identification and potential preventive trials, while others remain excluded. This disparity risks exacerbating health inequities across socioeconomic and geographic lines[167].
Consequently, labeling high-risk children presents a complex ethical landscape that demands careful navigation. It requires balancing the potential benefits of early identification with the risks of psychological harm, stigmatization, autonomy infringement, and inequity. Transparent communication, informed consent processes, psychosocial support systems, and strong confidentiality safeguards are essential to ensure that predictive testing is implemented in a manner that respects the dignity, rights, and well-being of children and their families. Therefore, addressing these ethical challenges requires careful communication, informed consent, and robust support systems to help families navigate the complex emotional and practical implications of a high-risk label. The benefits of early detection must be carefully weighed against the potential harm of the label itself.
The implementation of precision prevention strategies must be carefully managed to avoid widening existing health inequalities. Beyond the well-documented genomic data gap - where over 80% of genome-wide association studies participants are of European ancestry - broader structural and socioeconomic barriers present significant challenges to equitable care. For socioeconomically diverse populations, the high cost of multi-omic testing (genomics, metabolomics, microbiome) and the lack of insurance coverage for preventive screening are primary obstacles[181]. Furthermore, geographic disparities, such as the limited availability of specialized pediatric immunology clinics in rural or under
The progression from genetic susceptibility and autoantibody positivity to overt autoimmune disease is not uniform; it is shaped by a complex interplay of environmental exposures and healthcare access, both of which present significant challenges in preventive strategies for high-risk children[10]. Environmental factors - including infections, dietary habits, pollutant exposure, microbial diversity, and lifestyle practices - play a central role in immune system development and modulation of autoimmune risk. Yet, these exposures vary considerably across geographical regions, socioeconomic groups, cultural settings, and even between urban and rural environments[185,186]. For instance, children in industrialized countries may be more frequently exposed to air pollution and processed foods. In contrast, those in rural or resource-limited areas may experience recurrent infections or limited dietary diversity. Both extremes can disrupt immune tolerance and influence disease onset in distinct ways[187].
Adding to this complexity, the same environmental exposure does not have uniform effects across individuals. A viral infection, for example, may act as a potent trigger for TIDM in one genetically susceptible child while leaving another child with identical risk alleles unaffected[188]. Such variability makes it nearly impossible to design a universal pre
Healthcare access further compounds these challenges. In many parts of the world, children at elevated autoimmune risk face barriers to timely screening, early diagnosis, and preventive care due to the scarcity of specialized pediatric and immunology services[190]. Even within well-resourced health systems, inequities persist: Families from lower so
This variability in both exposures and healthcare access complicates efforts to standardize preventive strategies. What is feasible and effective in one population may be unrealistic or unsustainable in another. Moreover, the uneven global distribution of resources risks widening health disparities, as children in underserved regions remain disproportionately vulnerable to late diagnosis and preventable complications[193]. Addressing these inequities requires more than biomedical advances - it calls for public health measures and policy reforms that promote equitable access, adapt interventions to local contexts, and target modifiable environmental risk factors.
One of the most persistent challenges in autoimmune disease prevention is the lack of culturally adapted strategies that account for diverse dietary habits, health beliefs, and social structures. While much of the evidence supporting prevention derives from studies in Western or other high-income countries, the findings are not always directly applicable to other populations with different cultural, genetic, and environmental backgrounds[194]. For example, recommendations around dietary modification, breastfeeding practices, or exposure to environmental antigens may not align with traditional lifestyles, religious practices, or socioeconomic realities in certain regions. Without careful adaptation, pre
Cultural context also plays a central role in shaping perceptions of risk and acceptance of preventive interventions. In some societies, health-seeking behavior is deeply influenced by family hierarchies, traditional medicine, or stigmatization of chronic illness[196]. Labeling a child as “high-risk” for autoimmune disease may be met with fear, denial, or resistance, especially when the proposed interventions conflict with cultural norms or when access to healthcare is already limited[197]. Furthermore, preventive strategies such as vaccination, dietary restrictions, or stress-reduction interventions may be interpreted differently across communities, leading to variable uptake and effectiveness[198].
The globalization of research has highlighted that prevention cannot follow a one-size-fits-all model. Instead, practical approaches must integrate evidence-based medicine with cultural sensitivity. This requires engaging local healthcare providers, community leaders, and families in the design and dissemination of interventions, ensuring that the recommendations are linguistically accessible, respectful of religious practices, and compatible with local diets and resources[199]. For instance, recommendations for increased vitamin D intake may need to be tailored differently for populations with limited sun exposure due to clothing practices or where fortified foods are not readily available. Similarly, guidance on reducing cardiovascular risk in children with autoimmune disease should consider local food availability and socioeconomic constraints[200].
In addition, cultural adaptation extends beyond education and into systemic healthcare delivery. Interventions must be feasible within the structure of local health systems, where access to specialized care, diagnostic testing, and preventive therapies may be limited. Strategies that work well in resource-rich environments may fail in low-resource settings unless they are simplified and made sustainable[201]. Ultimately, culturally adapted prevention requires ongoing dialogue among researchers, clinicians, and communities to ensure that strategies are both scientifically sound and socially acceptable. By aligning medical recommendations with cultural values and realities, the long-term goal of reducing complications of autoimmune disease becomes more attainable and equitable across global populations[202].
The future of autoimmune disease prevention in high-risk children lies increasingly in the domain of precision medicine. Traditional prevention strategies often adopt a “one-size-fits-all” approach. Yet, the complexity of autoimmune disease etiology - shaped by genetic predisposition, environmental exposures, and individual lifestyle factors - demands a more tailored paradigm. Emerging tools such as PRS and comprehensive exposome profiling hold promise for advancing this shift toward precision prevention[203].
PRSs, which aggregate the cumulative effect of multiple genetic variants associated with autoimmune diseases, provide a quantifiable estimate of an individual’s inherited susceptibility. Unlike single-gene markers, PRS capture a broader genetic landscape, allowing clinicians to stratify children not only as “high-risk” or “low-risk” but also across a nuanced spectrum of susceptibility[204]. When applied early in life, these scores could guide decisions on monitoring intensity, the timing of preventive interventions, and the prioritization of resources for those most vulnerable.
Complementing PRS is the concept of the exposome, which encompasses the totality of environmental influences - ranging from infections, diet, pollutants, stress, and microbiome composition - that interact with the genome over time. By integrating exposome data with genetic risk, clinicians and researchers can begin to map gene-environment inte
The integration of PRS and exposome data can enable predictive models that go beyond static risk assessment to dynamic, individualized risk trajectories. Machine learning algorithms and advanced bioinformatics are increasingly being developed to process these complex, multidimensional datasets, paving the way for real-time risk prediction and adaptive prevention strategies[207]. Such an approach could inform not only surveillance intensity but also the tailoring of interventions, including dietary modifications, vaccination schedules, and microbiome-targeted therapies. Figure 13 shows an example of an integrated model for autoimmune disease prevention.
Despite this promise, several challenges remain before precision prevention can be widely implemented. The predictive accuracy of PRS across diverse populations remains limited, as most genomic data are derived from European-ancestry cohorts, which may restrict its applicability in other ethnic groups[208]. Similarly, exposome data collection requires standardized methodologies, longitudinal monitoring, and the integration of wearable technologies, all of which raise feasibility and cost concerns. Moreover, ethical considerations - including the handling of sensitive genetic infor
The convergence of polygenic risk scoring and exposome science offers a transformative vision for the future of autoimmune disease prevention in children. By moving from broad population-level recommendations to individualized risk-adapted strategies, precision prevention has the potential to optimize outcomes, reduce unnecessary interventions, and empower families with actionable knowledge[210]. However, rigorous validation, equitable implementation, and ethical frameworks will be essential to translate this vision into clinical practice.
Emerging therapeutic approaches are increasingly focused on modulating the gut microbiome to prevent or delay the onset of autoimmune diseases in genetically susceptible children. Traditional probiotics, while beneficial in some contexts, have shown inconsistent results due to strain variability, dosage challenges, and limited colonization potential[211]. This has driven interest toward next-generation probiotics - engineered or naturally occurring strains with more targeted immunomodulatory properties. They are emerging as a promising strategy for the prevention and management of autoimmune disorders, moving beyond traditional probiotic strains such as Lactobacillus and Bifidobacterium[212]. These novel probiotics include rationally selected commensal bacteria, such as Akkermansia muciniphila, Faecalibacterium prausnitzii, and Clostridium clusters IV and XIVa, which have demonstrated strong immunomodulatory and anti-inflammatory properties in preclinical and early clinical studies[213]. Unlike conventional probiotics, next-generation strains (Table 4) are selected for their ability to restore immune tolerance, regulate T-cell balance, and promote the production of beneficial metabolites, such as short-chain fatty acids, that strengthen the intestinal barrier and reduce systemic inflammation[214]. For example, Akkermansia muciniphila has been shown to enhance mucosal integrity. At the same time, Faecalibacterium prausnitzii is linked to the suppression of pro-inflammatory cytokines, both of which are relevant in conditions such as T1DM, IBD, and multiple sclerosis. Although the therapeutic potential is promising, the clinical translation of next-generation probiotics is still limited by challenges such as strain-specific effects, safety concerns, regulatory approval, and the need for personalized approaches that account for host genetics, microbiome composition, and environmental exposures[215]. Nevertheless, with advances in metagenomics, synthetic biology, and precision medicine, next-generation probiotics represent a transformative frontier in the prevention and treatment of autoimmune diseases.
| Candidate NGP | Key mechanism(s) | Relevance to autoimmune diseases |
| Akkermansia muciniphila | Enhances gut barrier integrity, increases mucin production, modulates Treg/Th17 balance | Associated with reduced inflammation; protective role in type 1 diabetes and multiple sclerosis models |
| Faecalibacterium prausnitzii | Produces butyrate (short-chain fatty acid), exerts anti-inflammatory effects via IL-10 induction and NF-κB inhibition | Lower abundance linked with IBD and rheumatoid arthritis; supplementation may restore tolerance |
| Bacteroides fragilis (polysaccharide A strain) | Promotes Treg differentiation and reduces pro-inflammatory cytokines | Shown to prevent colitis and experimental autoimmune encephalomyelitis in animal models |
| Roseburia species | Butyrate production strengthens the epithelial barrier and suppresses pro-inflammatory pathways | Reduced levels observed in IBD and type 1 diabetes; potential for restoring immune tolerance |
| Clostridium clusters IV and XIVa | Induce colonic Treg expansion, short-chain fatty acids production | Protective in colitis and systemic autoimmune models; contributes to mucosal immune balance |
| Prevotella histicola | Modulates dendritic cells and T cell responses, decreasing pro-inflammatory Th1/Th17 cells | Demonstrated efficacy in reducing MS-like symptoms in experimental models |
| Escherichia coli Nissle 1917 (engineered forms) | Enhances epithelial barrier, modulates innate immunity, and can be engineered for anti-inflammatory metabolite production | Shown protective effects in IBD; engineered strains under study for systemic autoimmunity |
Similarly, microbiota-based therapies, such as FMT, are being explored to restore microbial diversity and resilience in high-risk children. This procedure involves transferring a fecal sample from a healthy donor into the recipient’s gut to restore a balanced microbial community. While currently approved in some countries only for the treatment of Clostridioides difficile infection, FMT is being investigated for its potential to treat or prevent autoimmune conditions like IBD. Although still experimental in pediatrics, early data suggest that carefully screened and standardized FMT preparations may reestablish immune tolerance and reduce the risk of autoimmunity by reshaping the gut ecosystem[213,216].
These advanced strategies represent a shift towards precise, biologically targeted therapies. Instead of broad-spectrum interventions, future treatments will likely focus on a personalized approach to rebuild a resilient and diverse micro
Viral infections are known environmental triggers of autoimmune diseases, either by initiating immune dysregulation or by perpetuating chronic inflammation. This has led to the development of a promising new strategy called immunoprevention, which uses preventive vaccines to eliminate these infectious triggers in genetically susceptible individuals[217]. While no vaccine is currently approved specifically to prevent an autoimmune disease, this approach aims to prevent the “environmental spark” from igniting an autoimmune response. The relationship between vaccines and autoimmunity is complex; some vaccines are being investigated for their potential to reduce autoimmune risk, while the vast majority have no effect, and a minimal number have been linked to a theoretical increase in autoimmune risk (Table 5)[218]. The current focus is on developing vaccines to prevent infections strongly associated with certain au
| Vaccine | Target infection(s) | Direction of effect on autoimmune risk (population level) | Notable autoimmune-type adverse events (rare) | Evidence type/key findings |
| Rotavirus | Rotavirus gastroenteritis | Possible decrease in T1DM incidence in some large cohorts, while others report a neutral effect | No consistent autoimmune signal has been demonstrated | Large administrative and time-series cohort studies have yielded mixed results; some show a modest (approximately 33%) reduction in T1DM risk following a complete vaccine series in specific cohorts |
| MMR | Measles, mumps, rubella | Neutral. No proven increase in the risk of chronic autoimmune diseases | Immune thrombocytopenic purpura has a very rare association (approximately 1 per 40000 doses), which is typically self-limited. The risk of neurological complications from measles infection is far higher | Decades of evidence from large case-control studies, active surveillance systems, and analyses by advisory committees (e.g., ACIP) |
| Hepatitis B | Hepatitis B virus | Neutral. No increase in the incidence of multiple sclerosis or other autoimmune diseases | No consistently demonstrated autoimmune-type adverse events | Large nested case-control studies and cohort studies, including a landmark study published in the New England Journal of Medicine, have shown no association with MS |
| Meningococcal conjugate | Neisseria meningitidis | Neutral. No increased risk of autoimmune diseases | No causal link to GBS has been found in large cohort studies, despite initial post-licensure signals | Extensive pharmacoepidemiology and record-validated cohort studies have provided a reassuring safety profile |
| Pneumococcal (PCV13, PPSV23) | Streptococcus pneumoniae | Neutral. No increased risk of autoimmune diseases | None consistently demonstrated | Large-scale safety studies and post-licensure surveillance have found no association with autoimmune conditions |
| Varicella (chickenpox) | Varicella-zoster virus | Neutral. No increased risk of autoimmune diseases | Very rare cases of vasculitis or arthritis have been reported, but a causal link has not been established. The risk of these conditions from natural infection is higher | Extensive safety data from clinical trials and post-licensure surveillance systems |
| HPV | Human papillomavirus | Neutral. No increase in autoimmune diseases, including MS, IBD, and SLE, has been found | Very rare cases of GBS have been observed in some post-licensure analyses, but overall rates are not elevated compared to the background population | Extensive multinational cohort studies, case-control studies, and national surveillance registries have consistently shown a reassuring safety profile with no causal link |
| Influenza (seasonal) | Influenza A and B viruses | Neutral. Prevention of influenza infection significantly reduces the risk of post-infectious autoimmune complications | GBS is a very rare adverse event, with an estimated risk of approximately 1-2 cases per million doses, which is lower than the risk of GBS from influenza infection itself | Evidence from meta-analyses of randomized trials, large-scale surveillance data (e.g., from the CDC), and national cohorts |
| COVID-19 mRNA | SARS-CoV-2 | Neutral. No signal for chronic autoimmune disease; preventing infection reduces post-infectious autoimmunity | Myocarditis/pericarditis is a rare, typically mild adverse event, with the highest risk observed in adolescent and young adult males, particularly after the second dose. The risk of these conditions from COVID-19 infection itself is significantly higher | National surveillance (CDC’s V-safe and VAERS), international cohorts, and analyses published in reputable journals like JAMA have characterized these rare events |
| (Future) EBV vaccine | EBV | Potential decrease (hypothesized). Strong potential to reduce the incidence of MS and other EBV-linked autoimmune diseases | N/A; no licensed product available yet | Evidence is based on strong epidemiological and mechanistic links between EBV infection and autoimmune diseases; multiple vaccine platforms are currently in development |
| (Future) T1DM vaccine | N/A (Immunomodulatory) | Potential decrease (hypothesized). Aims to induce immune tolerance to prevent the autoimmune attack on the pancreas | N/A; no licensed product available yet | Multiple clinical trials are underway for both oral and parenteral immunomodulatory vaccines; early results for oral insulin and other agents have shown promise in delaying disease progression |
Several viruses and bacteria have been identified as potential triggers of autoimmune conditions through mechanisms such as molecular mimicry, in which a pathogen’s proteins closely resemble the body’s own proteins, prompting the immune system to attack healthy tissue mistakenly[219]. One prime example is Coxsackievirus B, a member of the enterovirus family, which has been strongly linked to the development of T1DM. These viruses can infect the pancreatic beta cells, leading to inflammation and subsequent autoimmune destruction. The development of a vaccine that prevents common enteroviral infections could, in theory, eliminate this trigger in at-risk children, thereby reducing the incidence of T1DM[220].
Another example is the Epstein-Barr virus (EBV), a ubiquitous herpesvirus that has been consistently associated with an increased risk of multiple sclerosis and SLE. While the exact mechanism is complex, EBV infection is believed to activate specific immune cells and contribute to the breach of self-tolerance[221,222]. The development of a prophylactic EBV vaccine, which is currently in clinical trials, could be a game-changer in preventing these and other EBV-associated autoimmune diseases[223]. In addition to EBV, other pathogens such as Helicobacter pylori and human herpesvirus 6 have been investigated for their potential roles in autoimmune pathogenesis, highlighting the broader relevance of pathogen-targeted prevention strategies[224].
The use of preventive vaccines for autoimmunity is a paradigm shift. Unlike traditional vaccines that aim to prevent a disease in a whole population, these vaccines would be particularly critical for targeted groups, such as children with a strong family history of a specific autoimmune disorder[218]. However, long-term studies are needed to establish whether preventing infections translates into measurable reductions in the incidence of autoimmune disease and to ensure safety in populations with a genetic predisposition to immune dysregulation. While challenges remain, including establishing a causal link between the infection and the autoimmune disease, this approach represents a powerful and practical avenue for preventing the development of these chronic conditions.
The future of autoimmune disease prevention is moving beyond generic dietary advice towards highly personalized nutritional strategies. This approach, known as personalized nutrition, uses advanced technologies such as metabolomics and microbiome profiling to create a diet tailored to an individual’s unique biological needs[225].
Metabolomics is the large-scale study of small molecules, or metabolites, within a biological system. These metabolites are the end products of metabolic processes and are influenced by a combination of a person’s genetics, diet, and lifestyle[226]. By analyzing a child’s metabolomic profile, clinicians can gain insights into their specific inflammatory pathways, nutrient deficiencies, and metabolic imbalances. For example, a metabolomics screen might reveal a low level of anti-inflammatory metabolites or a high level of pro-inflammatory compounds, providing a precise target for dietary intervention[227].
Microbiome profiling involves sequencing the genetic material of the microorganisms in a person’s gut to identify the specific bacterial species present and their relative abundance. A healthy microbiome is rich in diverse, beneficial bacteria, while a state of dysbiosis - an imbalance in the microbial community - is often linked to autoimmune risk[228]. By understanding a child’s unique microbial landscape, nutritionists can recommend specific prebiotics (fibers that feed beneficial bacteria) and probiotics to correct imbalances and foster a gut environment that supports immune tolerance[229].
By combining metabolomics and microbiome profiling data, clinicians can move beyond generalized recommendations toward a precision nutrition approach. For instance, a child with a genetic risk for IBD might have a metabolomic profile showing a low level of the anti-inflammatory metabolite butyrate[230]. Simultaneously, their microbiome profile might show a low abundance of the bacteria that produce this metabolite. This combined data would lead to a targeted dietary plan rich in specific fibers and possibly a next-generation probiotic supplement to correct both the microbial and metabolic deficiencies, thereby reducing their risk of disease. This innovative approach promises to make dietary interventions a more powerful, evidence-based tool for preventing autoimmune disease[231].
While this review provides a comprehensive framework for prevention, several significant challenges and limitations must be acknowledged. First, a significant challenge in synthesizing a global framework for prevention is the variability in the quality of epidemiological data. The rising incidence rates cited throughout this review must be interpreted within the context of changing medical practices. Specifically, ‘diagnostic drift’ - where improved screening protocols identify milder or subclinical cases that might have previously gone undetected - can lead to an apparent increase in disease prevalence. Furthermore, many of the landmark studies that form the basis of our understanding of pediatric autoimmunity (e.g., The Environmental Determinants of Diabetes in the Young, Pre-POINT) are susceptible to selection bias, as they typically involve highly motivated families or specific genetic subgroups. A more balanced assessment of these trends acknowledges that while the environmental impact is undeniable, the absolute rate of increase is subject to measurement error and ascertainment bias. Future research should prioritize standardized, population-based registries in diverse global settings to confirm these trends with greater certainty.
Second, the field of personalized prevention is nascent, and the long-term efficacy of many proposed interventions remains unproven. Much of the data is from observational studies or small-scale clinical trials, necessitating large randomized controlled trials to establish causality. Third, implementing such strategies faces major logistical and ethical hurdles. Widespread screening for preclinical biomarkers is costly and requires careful consideration of the psychosocial impact of labeling an asymptomatic child as “pre-symptomatic”. The real-world application of complex dietary, lifestyle, or microbial interventions can be challenging, as they require significant family commitment and financial resources. Fourth, the majority of research has focused on specific autoimmune diseases (e.g., T1DM and celiac disease), and more evidence is needed to apply these concepts to other conditions, such as JIA or lupus. Finally, the actual impact of this precision medicine approach will not be known until long-term follow-up studies can track disease trajectories over decades, a process that is both resource-intensive and complex to sustain.
Based on the integrated framework for preventing pediatric autoimmune diseases, a proactive approach is recommended across multiple domains. Clinicians should adopt a prevention-focused mindset, stay informed about emerging biomarkers, and engage in collaborative, multidisciplinary care models. For researchers, a priority is to conduct large-scale randomized controlled trials to validate the efficacy of preventive interventions and to develop non-invasive methods to assess the exposome. Researchers must also investigate the long-term ethical and psychosocial impacts of labeling children as high-risk. Finally, public health officials should develop and implement policies that promote early-life health, ensuring equitable access to care and to research funding. This collective effort is essential to translating scientific advancements into effective public health strategies to reduce the global burden of pediatric autoimmunity.
The rising incidence of pediatric autoimmune diseases demands a fundamental shift in medical strategy - from reacting to managing established diseases to proactively preventing it. This review provides a robust framework that integrates genetic, environmental, and immunological data to identify at-risk children and offers a tiered intervention approach. The core of this model rests on a multi-pronged strategy that begins with primordial prevention in the critical “first 1000 days” and extends to primary, secondary, and tertiary prevention. By leveraging advances in genomics, exposomics, and targeted immunotherapies such as teplizumab, we are moving closer to a future in which autoimmune diseases may be preventable rather than merely manageable. This comprehensive approach provides a roadmap for clinicians, researchers, and public health officials, offering a new path to combat the global burden of pediatric autoimmunity by altering disease trajectories and improving long-term health outcomes for the next generation.
| 1. | Grasso EA, Chiarelli F. Type 1 Diabetes and Other Autoimmune Disorders in Children. Pediatr Diabetes. 2024;2024:5082064. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 12] [Cited by in RCA: 12] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 2. | Ogrotis I, Koufakis T, Kotsa K. Changes in the Global Epidemiology of Type 1 Diabetes in an Evolving Landscape of Environmental Factors: Causes, Challenges, and Opportunities. Medicina (Kaunas). 2023;59:668. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 43] [Reference Citation Analysis (0)] |
| 3. | Segni M, Pucarelli I, Truglia S, Turriziani I, Serafinelli C, Conti F. High prevalence of antinuclear antibodies in children with thyroid autoimmunity. J Immunol Res. 2014;2014:150239. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 15] [Cited by in RCA: 23] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
| 4. | Hoffmann AA, Willi Y. Detecting genetic responses to environmental change. Nat Rev Genet. 2008;9:421-432. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 370] [Cited by in RCA: 319] [Article Influence: 17.7] [Reference Citation Analysis (0)] |
| 5. | Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an urgent call to action for improved understanding, diagnosis, treatment, and prevention. Curr Opin Immunol. 2023;80:102266. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 36] [Cited by in RCA: 350] [Article Influence: 116.7] [Reference Citation Analysis (0)] |
| 6. | Cárdenas-Roldán J, Rojas-Villarraga A, Anaya JM. How do autoimmune diseases cluster in families? A systematic review and meta-analysis. BMC Med. 2013;11:73. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 134] [Cited by in RCA: 164] [Article Influence: 12.6] [Reference Citation Analysis (0)] |
| 7. | Tettey P, Simpson S Jr, Taylor BV, van der Mei IA. The co-occurrence of multiple sclerosis and type 1 diabetes: shared aetiologic features and clinical implication for MS aetiology. J Neurol Sci. 2015;348:126-131. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 30] [Cited by in RCA: 39] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
| 8. | Cohn A, Sofia AM, Kupfer SS. Type 1 diabetes and celiac disease: clinical overlap and new insights into disease pathogenesis. Curr Diab Rep. 2014;14:517. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 79] [Cited by in RCA: 66] [Article Influence: 5.5] [Reference Citation Analysis (1)] |
| 9. | Serena G, Camhi S, Sturgeon C, Yan S, Fasano A. The Role of Gluten in Celiac Disease and Type 1 Diabetes. Nutrients. 2015;7:7143-7162. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 60] [Cited by in RCA: 43] [Article Influence: 3.9] [Reference Citation Analysis (4)] |
| 10. | Kumar M, Yip L, Wang F, Marty SE, Fathman CG. Autoimmune disease: genetic susceptibility, environmental triggers, and immune dysregulation. Where can we develop therapies? Front Immunol. 2025;16:1626082. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 7] [Cited by in RCA: 24] [Article Influence: 24.0] [Reference Citation Analysis (0)] |
| 11. | Shen Y, Fan N, Ma SX, Cheng X, Yang X, Wang G. Gut Microbiota Dysbiosis: Pathogenesis, Diseases, Prevention, and Therapy. MedComm (2020). 2025;6:e70168. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 127] [Cited by in RCA: 147] [Article Influence: 147.0] [Reference Citation Analysis (0)] |
| 12. | Fall CH. Fetal malnutrition and long-term outcomes. Nestle Nutr Inst Workshop Ser. 2013;74:11-25. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 60] [Cited by in RCA: 71] [Article Influence: 5.5] [Reference Citation Analysis (0)] |
| 13. | Camacho-Morales A, Caba M, García-Juárez M, Caba-Flores MD, Viveros-Contreras R, Martínez-Valenzuela C. Breastfeeding Contributes to Physiological Immune Programming in the Newborn. Front Pediatr. 2021;9:744104. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 15] [Cited by in RCA: 94] [Article Influence: 18.8] [Reference Citation Analysis (1)] |
| 14. | Capra ME, Aliverti V, Bellani AM, Berzieri M, Montani AG, Pisseri G, Sguerso T, Esposito S, Biasucci G. Breastfeeding and Non-Communicable Diseases: A Narrative Review. Nutrients. 2025;17:511. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 10] [Reference Citation Analysis (1)] |
| 15. | Karp DR. Redefining autoimmune diseases: the opportunity for precision and prevention. Trans Am Clin Climatol Assoc. 2025;135:356-369. [PubMed] |
| 16. | Olsen NJ, Okuda DT, Holers VM, Karp DR. Editorial: Understanding the concept of pre-clinical autoimmunity. Front Immunol. 2022;13:983310. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 7] [Reference Citation Analysis (0)] |
| 17. | Ashournia P, Sadeghi P, Rezaei N, Moradinejad MH, Ziaee V. Prevalence of Family History of Autoimmune Disorders in Juvenile Systemic Lupus Erythematosus. Maedica (Bucur). 2018;13:21-24. [PubMed] |
| 18. | Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol. 2005;14:175-182. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 120] [Cited by in RCA: 126] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 19. | Parkkola A, Laine AP, Karhunen M, Härkönen T, Ryhänen SJ, Ilonen J, Knip M; Finnish Pediatric Diabetes Register. HLA and non-HLA genes and familial predisposition to autoimmune diseases in families with a child affected by type 1 diabetes. PLoS One. 2017;12:e0188402. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 14] [Cited by in RCA: 20] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
| 20. | Frazzei G, van Vollenhoven RF, de Jong BA, Siegelaar SE, van Schaardenburg D. Preclinical Autoimmune Disease: a Comparison of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Multiple Sclerosis and Type 1 Diabetes. Front Immunol. 2022;13:899372. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 75] [Article Influence: 18.8] [Reference Citation Analysis (0)] |
| 21. | Yu L, Zhao Z, Steck AK. T1D Autoantibodies: room for improvement? Curr Opin Endocrinol Diabetes Obes. 2017;24:285-291. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 10] [Cited by in RCA: 21] [Article Influence: 2.3] [Reference Citation Analysis (0)] |
| 22. | TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann N Y Acad Sci. 2008;1150:1-13. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 237] [Cited by in RCA: 243] [Article Influence: 13.5] [Reference Citation Analysis (0)] |
| 23. | Al-Ewaidat OA, Naffaa MM. Emerging AI- and Biomarker-Driven Precision Medicine in Autoimmune Rheumatic Diseases: From Diagnostics to Therapeutic Decision-Making. Rheumato. 2025;5:17. [DOI] [Full Text] |
| 24. | Khan MF, Wang H. Environmental Exposures and Autoimmune Diseases: Contribution of Gut Microbiome. Front Immunol. 2019;10:3094. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 79] [Cited by in RCA: 101] [Article Influence: 16.8] [Reference Citation Analysis (0)] |
| 25. | Jung H, Jung HU, Baek EJ, Kwon SY, Kang JO, Lim JE, Oh B. Integration of risk factor polygenic risk score with disease polygenic risk score for disease prediction. Commun Biol. 2024;7:180. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 22] [Reference Citation Analysis (0)] |
| 26. | Ribeiro-Mourão F, Agrawal M, Torres J, Peter I. Intervention(s) in the Early-Life Period to Modulate Inflammatory Bowel Disease Risk: What Could Be the Impact? Inflamm Bowel Dis. 2025;31:S27-S40. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 1] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
| 27. | Lioret S, Harrar F, Boccia D, Hesketh KD, Kuswara K, Van Baaren C, Maritano S, Charles MA, Heude B, Laws R. The effectiveness of interventions during the first 1,000 days to improve energy balance-related behaviors or prevent overweight/obesity in children from socio-economically disadvantaged families of high-income countries: a systematic review. Obes Rev. 2023;24:e13524. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 37] [Reference Citation Analysis (0)] |
| 28. | Li DY, Wang L, Li L, Zhou S, Tan J, Tang C, Liao Q, Liu T, Wen L, Qi HB. Maternal vitamin D status and risk of gestational diabetes mellitus in twin pregnancies: a longitudinal twin pregnancies birth cohort study. Nutr J. 2024;23:41. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 29. | Bodur M, Yilmaz B, Ağagündüz D, Ozogul Y. Immunomodulatory Effects of Omega-3 Fatty Acids: Mechanistic Insights and Health Implications. Mol Nutr Food Res. 2025;69:e202400752. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 51] [Reference Citation Analysis (0)] |
| 30. | Potiris A, Daponte N, Moustakli E, Zikopoulos A, Kokkosi E, Arkouli N, Anagnostaki I, Vogiatzoglou AL, Tzeli M, Sarella A, Domali E, Stavros S. Prenatal Dietary Exposure to Endocrine Disruptors and Its Lasting Impact on Offspring Health. Toxics. 2025;13:864. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 10] [Reference Citation Analysis (0)] |
| 31. | Zhang C, Li L, Jin B, Xu X, Zuo X, Li Y, Li Z. The Effects of Delivery Mode on the Gut Microbiota and Health: State of Art. Front Microbiol. 2021;12:724449. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 129] [Cited by in RCA: 80] [Article Influence: 16.0] [Reference Citation Analysis (0)] |
| 32. | LaPoint P, Banks K, Bacorn M, Prasad R, Romero-Soto HN, Namasivayam S, Chen Q, Patel A, Levy S, Hourigan SK. Can Vaginal Seeding at Birth Improve Health Outcomes of Cesarean Section-Delivered Infants? A Scoping Review. Microorganisms. 2025;13:1236. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 5] [Reference Citation Analysis (0)] |
| 33. | Ames SR, Lotoski LC, Azad MB. Comparing early life nutritional sources and human milk feeding practices: personalized and dynamic nutrition supports infant gut microbiome development and immune system maturation. Gut Microbes. 2023;15:2190305. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 88] [Reference Citation Analysis (0)] |
| 34. | Fatimah, Massi MN, Febriani ADB, Hatta M, Karuniawati A, Rauf S, Wahyuni S, Hamid F, Alasiry E, Patellongi I, Permatasari TAE, Farsida. The role of exclusive breastfeeding on sIgA and lactoferrin levels in toddlers suffering from Acute Respiratory Infection: A cross-sectional study. Ann Med Surg (Lond). 2022;77:103644. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 8] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 35. | Choi EY, Bea S, Lee H, Choi A, Han JY, Kang EH, Shin JY. Exposure to antibiotics during pregnancy or early infancy and the risk of autoimmune disease in children: A nationwide cohort study in Korea. PLoS Med. 2025;22:e1004677. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 36. | Olvera Alvarez HA, Kubzansky LD, Campen MJ, Slavich GM. Early life stress, air pollution, inflammation, and disease: An integrative review and immunologic model of social-environmental adversity and lifespan health. Neurosci Biobehav Rev. 2018;92:226-242. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 73] [Cited by in RCA: 94] [Article Influence: 11.8] [Reference Citation Analysis (1)] |
| 37. | Palmer RF, Dempsey TT, Afrin LB. Chemical Intolerance and Mast Cell Activation: A Suspicious Synchronicity. J Xenobiot. 2023;13:704-718. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 38. | Ratsika A, Codagnone MC, O'Mahony S, Stanton C, Cryan JF. Priming for Life: Early Life Nutrition and the Microbiota-Gut-Brain Axis. Nutrients. 2021;13:423. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 67] [Cited by in RCA: 122] [Article Influence: 24.4] [Reference Citation Analysis (0)] |
| 39. | Andreou E, Papaneophytou C. Boosting Immunity Through Nutrition and Gut Health: A Narrative Review on Managing Allergies and Multimorbidity. Nutrients. 2025;17:1685. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 9] [Reference Citation Analysis (0)] |
| 40. | Christ A, Lauterbach M, Latz E. Western Diet and the Immune System: An Inflammatory Connection. Immunity. 2019;51:794-811. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 194] [Cited by in RCA: 633] [Article Influence: 105.5] [Reference Citation Analysis (2)] |
| 41. | Dimitriou A, Aggeletopoulou I, Triantos C. Optimizing Nutritional Balance: Integrating the Mediterranean Diet into Low-FODMAP Nutrition. Microorganisms. 2025;13:2085. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 42. | Rondinella D, Raoul PC, Valeriani E, Venturini I, Cintoni M, Severino A, Galli FS, Mora V, Mele MC, Cammarota G, Gasbarrini A, Rinninella E, Ianiro G. The Detrimental Impact of Ultra-Processed Foods on the Human Gut Microbiome and Gut Barrier. Nutrients. 2025;17:859. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 104] [Cited by in RCA: 67] [Article Influence: 67.0] [Reference Citation Analysis (1)] |
| 43. | Hagström N, Koochek A, Warensjö Lemming E, Öman A, Arnell H, Berntson L. Exploring nutritional risks of the specific carbohydrate diet: food and nutrient intake in children with juvenile idiopathic arthritis. J Nutr Sci. 2025;14:e9. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 44. | Aranow C. Vitamin D and the immune system. J Investig Med. 2011;59:881-886. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1002] [Cited by in RCA: 821] [Article Influence: 54.7] [Reference Citation Analysis (7)] |
| 45. | Balasooriya NN, Elliott TM, Neale RE, Vasquez P, Comans T, Gordon LG. The association between vitamin D deficiency and multiple sclerosis: an updated systematic review and meta-analysis. Mult Scler Relat Disord. 2024;90:105804. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 27] [Reference Citation Analysis (0)] |
| 46. | Altieri B, Muscogiuri G, Barrea L, Mathieu C, Vallone CV, Mascitelli L, Bizzaro G, Altieri VM, Tirabassi G, Balercia G, Savastano S, Bizzaro N, Ronchi CL, Colao A, Pontecorvi A, Della Casa S. Does vitamin D play a role in autoimmune endocrine disorders? A proof of concept. Rev Endocr Metab Disord. 2017;18:335-346. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 106] [Cited by in RCA: 129] [Article Influence: 14.3] [Reference Citation Analysis (0)] |
| 47. | Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75:645-662. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 895] [Cited by in RCA: 926] [Article Influence: 71.2] [Reference Citation Analysis (35)] |
| 48. | Bärebring L, Nwaru BI, Lamberg-Allardt C, Thorisdottir B, Ramel A, Söderlund F, Arnesen EK, Dierkes J, Åkesson A. Supplementation with long chain n-3 fatty acids during pregnancy, lactation, or infancy in relation to risk of asthma and atopic disease during childhood: a systematic review and meta-analysis of randomized controlled clinical trials. Food Nutr Res. 2022;66. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 20] [Reference Citation Analysis (0)] |
| 49. | Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, Brough HA, Phippard D, Basting M, Feeney M, Turcanu V, Sever ML, Gomez Lorenzo M, Plaut M, Lack G; LEAP Study Team. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372:803-813. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1887] [Cited by in RCA: 1568] [Article Influence: 142.5] [Reference Citation Analysis (6)] |
| 50. | Zhang S, Marken I, Stubbendorff A, Ericson U, Qi L, Sonestedt E, Borné Y. The EAT-Lancet Diet Index, Plasma Proteins, and Risk of Heart Failure in a Population-Based Cohort. JACC Heart Fail. 2024;12:1197-1208. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 36] [Article Influence: 18.0] [Reference Citation Analysis (0)] |
| 51. | Pardali EC, Gkouvi A, Gkouskou KK, Manolakis AC, Tsigalou C, Goulis DG, Bogdanos DP, Grammatikopoulou MG. Autoimmune protocol diet: A personalized elimination diet for patients with autoimmune diseases. Metabol Open. 2025;25:100342. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 8] [Reference Citation Analysis (0)] |
| 52. | Kotchetkoff ECA, de Oliveira LCL, Sarni ROS. Elimination diet in food allergy: friend or foe? J Pediatr (Rio J). 2024;100 Suppl 1:S65-S73. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 9] [Article Influence: 4.5] [Reference Citation Analysis (2)] |
| 53. | Gunasekeera V, Mendall MA, Chan D, Kumar D. Treatment of Crohn's Disease with an IgG4-Guided Exclusion Diet: A Randomized Controlled Trial. Dig Dis Sci. 2016;61:1148-1157. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 40] [Cited by in RCA: 56] [Article Influence: 5.6] [Reference Citation Analysis (3)] |
| 54. | Scheller B, Winter C, Zamyad J, Felmlee K, Heard D. The Successful Management Of Ulcerative Colitis With A Nutritional Intervention: A Case Report. Integr Med (Encinitas). 2019;18:40-47. [PubMed] |
| 55. | Verma A, Rani S, Verma S, Khanna A. Adherence to gluten free diet and problems faced by children with celiac disease and type 1 diabetes mellitus. J Family Med Prim Care. 2024;13:4252-4255. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 56. | Munjidah A, Masita ED, Novianti H, Dewi UM. The efficacy of implementing family-centered care in child feeding practices. Healthc Low-Resour Settings. 2024;12:11964. [DOI] [Full Text] |
| 57. | Mahmood L, Flores-Barrantes P, Moreno LA, Manios Y, Gonzalez-Gil EM. The Influence of Parental Dietary Behaviors and Practices on Children's Eating Habits. Nutrients. 2021;13:1138. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 19] [Cited by in RCA: 229] [Article Influence: 45.8] [Reference Citation Analysis (1)] |
| 58. | Mattei J, Alfonso C. Strategies for Healthy Eating Promotion and Behavioral Change Perceived as Effective by Nutrition Professionals: A Mixed-Methods Study. Front Nutr. 2020;7:114. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 9] [Cited by in RCA: 17] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
| 59. | Wiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies. Nutrients. 2021;13:886. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 405] [Cited by in RCA: 324] [Article Influence: 64.8] [Reference Citation Analysis (2)] |
| 60. | Hunter P. Public Health struggles to square hygiene with diversity: Research on the link between microbiomes and immune function puts the “hygiene hypothesis” to rest. EMBO Rep. 2020;21:e51540. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 5] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 61. | Dogra SK, Kwong Chung C, Wang D, Sakwinska O, Colombo Mottaz S, Sprenger N. Nurturing the Early Life Gut Microbiome and Immune Maturation for Long Term Health. Microorganisms. 2021;9:2110. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 83] [Cited by in RCA: 68] [Article Influence: 13.6] [Reference Citation Analysis (1)] |
| 62. | Gensollen T, Blumberg RS. Correlation between early-life regulation of the immune system by microbiota and allergy development. J Allergy Clin Immunol. 2017;139:1084-1091. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 68] [Cited by in RCA: 103] [Article Influence: 11.4] [Reference Citation Analysis (0)] |
| 63. | Patangia DV, Anthony Ryan C, Dempsey E, Paul Ross R, Stanton C. Impact of antibiotics on the human microbiome and consequences for host health. Microbiologyopen. 2022;11:e1260. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 640] [Cited by in RCA: 505] [Article Influence: 126.3] [Reference Citation Analysis (1)] |
| 64. | Oh SJ, Kim HJ, Lee CK; Big Data Research Group (BDRG) of the Korean Society of Gastroenterology. A dose-dependent increase in the risk of inflammatory bowel disease after exposure to broad-spectrum antibiotics: A national population study in Korea. Aliment Pharmacol Ther. 2023;58:191-206. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4] [Cited by in RCA: 16] [Article Influence: 5.3] [Reference Citation Analysis (0)] |
| 65. | Zhang Y, Xue G, Wang F, Zhang J, Xu L, Yu C. The impact of antibiotic exposure on antibiotic resistance gene dynamics in the gut microbiota of inflammatory bowel disease patients. Front Microbiol. 2024;15:1382332. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 11] [Reference Citation Analysis (0)] |
| 66. | Li S, Liu J, Zhang X, Gu Q, Wu Y, Tao X, Tian T, Pan G, Chu M. The Potential Impact of Antibiotic Exposure on the Microbiome and Human Health. Microorganisms. 2025;13:602. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 20] [Reference Citation Analysis (0)] |
| 67. | Feng JJ, Maddirala NR, Saint Fleur A, Zhou F, Yu D, Wei F, Zhang Y. Gut Microbiome and Immune System Crosstalk in Chronic Inflammatory Diseases: A Narrative Review of Mechanisms and Therapeutic Opportunities. Microorganisms. 2025;13:2516. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 8] [Cited by in RCA: 13] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
| 68. | Pelucchi C, Chatenoud L, Turati F, Galeone C, Moja L, Bach JF, La Vecchia C. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23:402-414. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 224] [Cited by in RCA: 176] [Article Influence: 12.6] [Reference Citation Analysis (3)] |
| 69. | Yoo S, Jung SC, Kwak K, Kim JS. The Role of Prebiotics in Modulating Gut Microbiota: Implications for Human Health. Int J Mol Sci. 2024;25:4834. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 118] [Article Influence: 59.0] [Reference Citation Analysis (0)] |
| 70. | Ugwu OP, Alum EU, Okon MB, Obeagu EI. Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 2024;103:e38088. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 8] [Cited by in RCA: 26] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
| 71. | Karisola P, Alenius H. Environmental determinants of immune tolerance in asthma and allergy. Immunol Lett. 2026;277:107102. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 72. | Costenbader KH, Karlson EW. Cigarette smoking and autoimmune disease: what can we learn from epidemiology? Lupus. 2006;15:737-745. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 142] [Cited by in RCA: 164] [Article Influence: 16.4] [Reference Citation Analysis (0)] |
| 73. | Cole E, Brown TA, Pinkerton KE, Postma B, Malany K, Yang M, Kim YJ, Hamilton RF Jr, Holian A, Cho YH. Perinatal exposure to environmental tobacco smoke is associated with changes in DNA methylation that precede the adult onset of lung disease in a mouse model. Inhal Toxicol. 2017;29:435-442. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 13] [Cited by in RCA: 11] [Article Influence: 1.4] [Reference Citation Analysis (0)] |
| 74. | Schug TT, Janesick A, Blumberg B, Heindel JJ. Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol. 2011;127:204-215. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 734] [Cited by in RCA: 739] [Article Influence: 49.3] [Reference Citation Analysis (0)] |
| 75. | de Paula LCP, Alves C. Food packaging and endocrine disruptors. J Pediatr (Rio J). 2024;100 Suppl 1:S40-S47. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 15] [Article Influence: 7.5] [Reference Citation Analysis (0)] |
| 76. | Betts KS. Plastics and food sources: dietary intervention to reduce BPA and DEHP. Environ Health Perspect. 2011;119:A306. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4] [Cited by in RCA: 5] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
| 77. | Bach JF. Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun. 2001;16:347-353. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 64] [Cited by in RCA: 64] [Article Influence: 2.6] [Reference Citation Analysis (0)] |
| 78. | Laupèze B, Del Giudice G, Doherty MT, Van der Most R. Vaccination as a preventative measure contributing to immune fitness. NPJ Vaccines. 2021;6:93. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 7] [Cited by in RCA: 51] [Article Influence: 10.2] [Reference Citation Analysis (0)] |
| 79. | Nederlof RA, Sainmaa S, Wissink-Argilaga N, Koo B, Bakker J. Preventative Vaccination of Nonhuman Primates. J Zool Bot Gardens. 2025;6:8. [DOI] [Full Text] |
| 80. | Cataldi JR, Kerns ME, O'Leary ST. Evidence-based strategies to increase vaccination uptake: a review. Curr Opin Pediatr. 2020;32:151-159. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 36] [Cited by in RCA: 100] [Article Influence: 16.7] [Reference Citation Analysis (0)] |
| 81. | Ashley MJ, Ferrence R. Reducing children's exposure to environmental tobacco smoke in homes: issues and strategies. Tob Control. 1998;7:61-65. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 95] [Cited by in RCA: 102] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
| 82. | Wang Y, Huang Z, Yang M, Wang F, Xiao S. Reducing environmental tobacco smoke exposure of preschool children: a randomized controlled trial of class-based health education and smoking cessation counseling for caregivers. Int J Environ Res Public Health. 2015;12:692-709. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 6] [Cited by in RCA: 12] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
| 83. | Bonifacio E, Coelho R, Ewald DA, Gemulla G, Hubmann M, Jarosz-Chobot P, Kohls M, Kordonouri O, Lampasona V, Narendran P, Pociot F, Šumník Z, Szypowska A, Zapardiel-Gonzalo J, Ziegler AG. The efficacy of islet autoantibody screening with or without genetic pre-screening strategies for the identification of presymptomatic type 1 diabetes. Diabetologia. 2025;68:1101-1107. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 8] [Reference Citation Analysis (0)] |
| 84. | Regnell SE, Lernmark Å. Early prediction of autoimmune (type 1) diabetes. Diabetologia. 2017;60:1370-1381. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 155] [Cited by in RCA: 130] [Article Influence: 14.4] [Reference Citation Analysis (0)] |
| 85. | Sabbah E, Savola K, Kulmala P, Reijonen H, Veijola R, Vähäsalo P, Karjalainen J, Ilonen J, Akerblom HK, Knip M. Disease-associated autoantibodies and HLA-DQB1 genotypes in children with newly diagnosed insulin-dependent diabetes mellitus (IDDM). The Childhood Diabetes in Finland Study Group. Clin Exp Immunol. 1999;116:78-83. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 25] [Cited by in RCA: 31] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
| 86. | Ghalwash M, Anand V, Lou O, Martin F, Rewers M, Ziegler AG, Toppari J, Hagopian WA, Veijola R; Type 1 Diabetes Intelligence Study Group. Islet autoantibody screening in at-risk adolescents to predict type 1 diabetes until young adulthood: a prospective cohort study. Lancet Child Adolesc Health. 2023;7:261-268. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4] [Cited by in RCA: 18] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 87. | Costa MS, Pegoraro GR, Silva CSF, Schneider A, Schadock I, Botelho FT, Barros CC. Association of HLA-DQ2 and HLA-DQ8 risk alleles to intestinal injury and serology in patients with celiac disease. Rev Nutr. 2024;37:e220188. [DOI] [Full Text] |
| 88. | Sciurti M, Fornaroli F, Gaiani F, Bonaguri C, Leandro G, Di Mario F, De' Angelis GL. Genetic susceptibilty and celiac disease: what role do HLA haplotypes play? Acta Biomed. 2018;89:17-21. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 25] [Reference Citation Analysis (0)] |
| 89. | Ridha MF, Al Zubaidi MA. Thyroid auto immune antibodies in children with Type-I Diabetes mellitus in relation to diabetes control. Pak J Med Sci. 2019;35:969-973. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 5] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
| 90. | Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M. The Diagnosis and Treatment of Systemic Lupus Erythematosus. Dtsch Arztebl Int. 2015;112:423-432. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 26] [Cited by in RCA: 80] [Article Influence: 8.0] [Reference Citation Analysis (0)] |
| 91. | Salley CG, Bakula DM, Driscoll CFB, Flanagan-Priore C, Kapke TL, Moore RM, Parris KR, Sharkey CM. Call to Action: Screening and Addressing Caregiver Mental Health Needs within all Pediatric Medical Subspecialty Settings as Standard of Care. Clin Pract Pediatr Psychol. 2024;12:328-338. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 6] [Cited by in RCA: 17] [Article Influence: 8.5] [Reference Citation Analysis (0)] |
| 92. | Simmons KM, Youngkin E, Alkanani A, Miao D, McDaniel K, Yu L, Michels AW. Screening children for type 1 diabetes-associated antibodies at community health fairs. Pediatr Diabetes. 2019;20:909-914. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 11] [Article Influence: 1.6] [Reference Citation Analysis (0)] |
| 93. | Orzan A, Novac C, Mihu M, Tirgoviste CI, Balgradean M. Type 1 Diabetes and Thyroid Autoimmunity in Children. Maedica (Bucur). 2016;11:308-312. [PubMed] |
| 94. | Kyritsi EM, Kanaka-Gantenbein C. Autoimmune Thyroid Disease in Specific Genetic Syndromes in Childhood and Adolescence. Front Endocrinol (Lausanne). 2020;11:543. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 27] [Cited by in RCA: 64] [Article Influence: 10.7] [Reference Citation Analysis (1)] |
| 95. | Altaş U, Ertem D. Evaluation of Growth in Children with Inflammatory Bowel Disease. Children (Basel). 2024;11:1038. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 96. | van Dommelen P, Grote FK, Oostdijk W, Keizer-Schrama SM, Boersma B, Damen GM, Csizmadia CG, Verkerk PH, Wit JM, van Buuren S. Screening rules for growth to detect celiac disease: a case-control simulation study. BMC Pediatr. 2008;8:35. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 12] [Cited by in RCA: 15] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 97. | Eremciuc R, Revenco N, Gheonea C. Algorithm for Growth Evaluation in Juvenile Idiopathic Arthritis. Curr Health Sci J. 2024;50:207-214. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 98. | Oleske DM. Screening and Surveillance for Promoting Population Health. In: Epidemiology and the Delivery of Health Care Services. Boston, MA: Springer, 2009: 131-150. [RCA] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 4] [Article Influence: 0.2] [Reference Citation Analysis (0)] |
| 99. | Choi MY, Costenbader KH. Understanding the Concept of Pre-Clinical Autoimmunity: Prediction and Prevention of Systemic Lupus Erythematosus: Identifying Risk Factors and Developing Strategies Against Disease Development. Front Immunol. 2022;13:890522. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 26] [Cited by in RCA: 43] [Article Influence: 10.8] [Reference Citation Analysis (0)] |
| 100. | Christensen C, Knudsen A, Arnesen EK, Hatlebakk JG, Sletten IS, Fadnes LT. Diet, Food, and Nutritional Exposures and Inflammatory Bowel Disease or Progression of Disease: an Umbrella Review. Adv Nutr. 2024;15:100219. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 58] [Cited by in RCA: 77] [Article Influence: 38.5] [Reference Citation Analysis (0)] |
| 101. | Randeni N, Bordiga M, Xu B. A Comprehensive Review of the Triangular Relationship among Diet-Gut Microbiota-Inflammation. Int J Mol Sci. 2024;25:9366. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 57] [Reference Citation Analysis (2)] |
| 102. | Kriegel MA, Manson JE, Costenbader KH. Does vitamin D affect risk of developing autoimmune disease?: a systematic review. Semin Arthritis Rheum. 2011;40:512-531.e8. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 141] [Cited by in RCA: 118] [Article Influence: 7.9] [Reference Citation Analysis (0)] |
| 103. | Konijeti GG, Arora P, Boylan MR, Song Y, Huang S, Harrell F, Newton-Cheh C, O'Neill D, Korzenik J, Wang TJ, Chan AT. Vitamin D Supplementation Modulates T Cell-Mediated Immunity in Humans: Results from a Randomized Control Trial. J Clin Endocrinol Metab. 2016;101:533-538. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 29] [Cited by in RCA: 49] [Article Influence: 4.9] [Reference Citation Analysis (0)] |
| 104. | Acevedo-Román A, Pagán-Zayas N, Velázquez-Rivera LI, Torres-Ventura AC, Godoy-Vitorino F. Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches. Int J Mol Sci. 2024;25:9715. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 77] [Cited by in RCA: 67] [Article Influence: 33.5] [Reference Citation Analysis (1)] |
| 105. | Brockway M. The role of antibiotic exposure and the effects of breastmilk and human milk feeding on the developing infant gut microbiome. Front Public Health. 2024;12:1408246. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 11] [Reference Citation Analysis (0)] |
| 106. | Sadiq IZ. Lifestyle medicine as a modality for prevention and management of chronic diseases. J Taibah Univ Med Sci. 2023;18:1115-1117. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 22] [Reference Citation Analysis (0)] |
| 107. | Abe M, Abe H. Lifestyle medicine - An evidence based approach to nutrition, sleep, physical activity, and stress management on health and chronic illness. Pers Med Universe. 2019;8:3-9. [DOI] [Full Text] |
| 108. | AbdulRaheem Y. Unveiling the Significance and Challenges of Integrating Prevention Levels in Healthcare Practice. J Prim Care Community Health. 2023;14:21501319231186500. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 110] [Reference Citation Analysis (0)] |
| 109. | Ruscitti P, Nunziato M, Caso F, Scarpa R, Di Maggio F, Giacomelli R, Salvatore F. Prevention of rheumatoid arthritis using a familial predictive medicine approach. Autoimmun Rev. 2024;23:103653. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 110. | Herold KC, Bundy BN, Long SA, Bluestone JA, DiMeglio LA, Dufort MJ, Gitelman SE, Gottlieb PA, Krischer JP, Linsley PS, Marks JB, Moore W, Moran A, Rodriguez H, Russell WE, Schatz D, Skyler JS, Tsalikian E, Wherrett DK, Ziegler AG, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381:603-613. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 984] [Cited by in RCA: 882] [Article Influence: 126.0] [Reference Citation Analysis (1)] |
| 111. | Horneff G, Fitter S, Foeldvari I, Minden K, Kuemmerle-Deschner J, Tzaribacev N, Thon A, Borte M, Ganser G, Trauzeddel R, Huppertz HI. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther. 2012;14:R230. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 64] [Cited by in RCA: 56] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 112. | Zhao LP, Papadopoulos GK, Skyler JS, Parikh HM, Kwok WW, Bondinas GP, Moustakas AK, Wang R, Pyo CW, Nelson WC, Geraghty DE, Lernmark Å. Oral Insulin Delay of Stage 3 Type 1 Diabetes Revisited in HLA DR4-DQ8 Participants in the TrialNet Oral Insulin Prevention Trial (TN07). Diabetes Care. 2024;47:1608-1616. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 19] [Cited by in RCA: 17] [Article Influence: 8.5] [Reference Citation Analysis (0)] |
| 113. | Ryhänen SJ, Härkönen T, Siljander H, Näntö-Salonen K, Simell T, Hyöty H, Ilonen J, Veijola R, Simell O, Knip M. Impact of intranasal insulin on insulin antibody affinity and isotypes in young children with HLA-conferred susceptibility to type 1 diabetes. Diabetes Care. 2011;34:1383-1388. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 7] [Cited by in RCA: 9] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
| 114. | Ziegler AG, Achenbach P, Weiß A, Berner R, Casteels K, Elding Larsson H, Haupt F, Hommel A, Jacobs A, Kordonouri O, Lundgren M, Ołtarzewski M, Pfirrmann M, Snape MD, Szypowska A, Todd JA, Vatish M, von dem Berge T, Winkler C, Bonifacio E; GPPAD-POInT Study Group. Efficacy of once-daily, high-dose, oral insulin immunotherapy in children genetically at risk for type 1 diabetes (POInT): a European, randomised, placebo-controlled, primary prevention trial. Lancet. 2025;406:2564-2576. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 7] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
| 115. | Rossi M, Maurano F, Luongo D. Immunomodulatory strategies for celiac disease. Int Rev Immunol. 2005;24:479-499. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5] [Cited by in RCA: 6] [Article Influence: 0.3] [Reference Citation Analysis (0)] |
| 116. | Wang YS, Liang SS, Ren JJ, Wang ZY, Deng XX, Liu WD, Yan YL, Song GH, Li XX. The Effects of Selenium Supplementation in the Treatment of Autoimmune Thyroiditis: An Overview of Systematic Reviews. Nutrients. 2023;15:3194. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 16] [Reference Citation Analysis (0)] |
| 117. | Stathopoulos P, Dalakas MC. Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases. Neurotherapeutics. 2022;19:691-710. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 21] [Cited by in RCA: 52] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
| 118. | Chandrashekara S. The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J Pharmacol. 2012;44:665-671. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 39] [Cited by in RCA: 59] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 119. | Xiang Y, Zhang M, Jiang D, Su Q, Shi J. The role of inflammation in autoimmune disease: a therapeutic target. Front Immunol. 2023;14:1267091. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 129] [Reference Citation Analysis (0)] |
| 120. | Nagy G, Szekely TE, Somogyi A, Herold M, Herold Z. New therapeutic approaches for type 1 diabetes: Disease-modifying therapies. World J Diabetes. 2022;13:835-850. [PubMed] [DOI] [Full Text] |
| 121. | Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30:S157-S162. [PubMed] |
| 122. | Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol. 2015;11:276-289. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 277] [Cited by in RCA: 351] [Article Influence: 31.9] [Reference Citation Analysis (0)] |
| 123. | Peyronel F, Rossi GM, Palazzini G, Odone L, Errichiello C, Emmi G, Vaglio A. Early-onset lupus nephritis. Clin Kidney J. 2024;17:sfae212. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 12] [Reference Citation Analysis (0)] |
| 124. | Bose B, Silverman ED, Bargman JM. Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis. 2014;63:667-676. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 33] [Cited by in RCA: 29] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
| 125. | Ehlers MR. Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med. 2016;64:7-13. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 13] [Cited by in RCA: 20] [Article Influence: 2.2] [Reference Citation Analysis (0)] |
| 126. | Gavin JP, Rossiter L, Fenerty V, Leese J, Adams J, Hammond A, Davidson E, Backman CL. The Impact of Occupational Therapy on the Self-Management of Rheumatoid Arthritis: A Mixed Methods Systematic Review. ACR Open Rheumatol. 2024;6:214-249. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 8] [Reference Citation Analysis (0)] |
| 127. | Yang CY, Leung PS, Adamopoulos IE, Gershwin ME. The implication of vitamin D and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2013;45:217-226. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 236] [Cited by in RCA: 214] [Article Influence: 16.5] [Reference Citation Analysis (0)] |
| 128. | McMahon M, Hahn BH, Skaggs BJ. Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol. 2011;7:227-241. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 91] [Cited by in RCA: 88] [Article Influence: 5.9] [Reference Citation Analysis (0)] |
| 129. | Woo P. Theoretical and practical basis for early aggressive therapy in paediatric autoimmune disorders. Curr Opin Rheumatol. 2009;21:552-557. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 18] [Cited by in RCA: 16] [Article Influence: 0.9] [Reference Citation Analysis (0)] |
| 130. | Tubiana-Rufi N. [Patient education for children and adolescents with chronic diseases]. Presse Med. 2009;38:1805-1813. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 20] [Cited by in RCA: 10] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
| 131. | Chow AJ, Saad A, Al-Baldawi Z, Iverson R, Skidmore B, Jordan I, Pallone N, Smith M, Chakraborty P, Brehaut J, Cohen E, Dyack S, Gillis J, Goobie S, Greenberg CR, Hayeems R, Hutton B, Inbar-Feigenberg M, Jain-Ghai S, Khangura S, MacKenzie JJ, Mitchell JJ, Moazin Z, Nicholls SG, Pender A, Prasad C, Schulze A, Siriwardena K, Sparkes RN, Speechley KN, Stockler S, Taljaard M, Teitelbaum M, Trakadis Y, Van Karnebeek C, Walia JS, Wilson K, Potter BK. Family-centred care interventions for children with chronic conditions: A scoping review. Health Expect. 2024;27:e13897. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 14] [Reference Citation Analysis (0)] |
| 132. | Elbilgahy AA, Alemam DS, Hashem SF, Abozed HW. Empowering families: the role of family-centered programs in alleviating fatigue for chronically ill children and their parents. BMC Pediatr. 2025;25:420. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 5] [Reference Citation Analysis (0)] |
| 133. | Chartrand J, Shea B, Hutton B, Dingwall O, Kakkar A, Chartrand M, Poulin A, Backman C. Patient- and family-centred care transition interventions for adults: a systematic review and meta-analysis of RCTs. Int J Qual Health Care. 2023;35:mzad102. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 17] [Reference Citation Analysis (0)] |
| 134. | Hatun Ş, Gökçe T, Can E, Eviz E, Karakuş KE, Smart C, Hanas R, Yeşiltepe Mutlu G. Current Management of Type 1 Diabetes in Children: Guideline-based Expert Opinions and Recommendations. J Clin Res Pediatr Endocrinol. 2024;16:245-255. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 135. | Di Ludovico A, La Bella S, Di Donato G, Felt J, Chiarelli F, Breda L. The benefits of physical therapy in juvenile idiopathic arthritis. Rheumatol Int. 2023;43:1563-1572. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 8] [Article Influence: 2.7] [Reference Citation Analysis (0)] |
| 136. | Piticchio T, Frasca F, Malandrino P, Trimboli P, Carrubba N, Tumminia A, Vinciguerra F, Frittitta L. Effect of gluten-free diet on autoimmune thyroiditis progression in patients with no symptoms or histology of celiac disease: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1200372. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 7] [Cited by in RCA: 18] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 137. | Ashcraft LE, Asato M, Houtrow AJ, Kavalieratos D, Miller E, Ray KN. Parent Empowerment in Pediatric Healthcare Settings: A Systematic Review of Observational Studies. Patient. 2019;12:199-212. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 29] [Cited by in RCA: 57] [Article Influence: 8.1] [Reference Citation Analysis (0)] |
| 138. | Castillo C, Kitsos E. Transitions From Pediatric to Adult Care. Glob Pediatr Health. 2017;4:2333794X17744946. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 9] [Cited by in RCA: 30] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
| 139. | Kuo DZ, Houtrow AJ, Arango P, Kuhlthau KA, Simmons JM, Neff JM. Family-centered care: current applications and future directions in pediatric health care. Matern Child Health J. 2012;16:297-305. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 486] [Cited by in RCA: 509] [Article Influence: 36.4] [Reference Citation Analysis (0)] |
| 140. | Kirkbride JB, Anglin DM, Colman I, Dykxhoorn J, Jones PB, Patalay P, Pitman A, Soneson E, Steare T, Wright T, Griffiths SL. The social determinants of mental health and disorder: evidence, prevention and recommendations. World Psychiatry. 2024;23:58-90. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 859] [Cited by in RCA: 615] [Article Influence: 307.5] [Reference Citation Analysis (0)] |
| 141. | Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, Mason J, Sattar N, McMurray JJV, McInnes IB, Khunti K, Cambridge G. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401:1878-1890. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 571] [Reference Citation Analysis (0)] |
| 142. | Magge SN. Cardiovascular Risk in Children and Adolescents with Type 1 and Type 2 Diabetes Mellitus. Curr Cardiovasc Risk Rep. 2012;6:591-600. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 6] [Cited by in RCA: 8] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
| 143. | Semalulu T, Tago A, Zhao K, Tselios K. Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician. Immunotargets Ther. 2023;12:175-186. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 13] [Cited by in RCA: 17] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
| 144. | Choi MY, Hahn J, Malspeis S, Stevens EF, Karlson EW, Sparks JA, Yoshida K, Kubzansky L, Costenbader KH. Association of a Combination of Healthy Lifestyle Behaviors With Reduced Risk of Incident Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022;74:274-283. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 33] [Cited by in RCA: 28] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
| 145. | Gonder-Frederick L. Lifestyle modifications in the management of type 1 diabetes: still relevant after all these years? Diabetes Technol Ther. 2014;16:695-698. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 11] [Cited by in RCA: 12] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
| 146. | Di Marcello F, Di Donato G, d'Angelo DM, Breda L, Chiarelli F. Bone Health in Children with Rheumatic Disorders: Focus on Molecular Mechanisms, Diagnosis, and Management. Int J Mol Sci. 2022;23:5725. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 15] [Article Influence: 3.8] [Reference Citation Analysis (0)] |
| 147. | Alsufyani KA, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Nadel H, Malleson PN. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol. 2005;32:729-733. [PubMed] |
| 148. | Verga Răuță GI, Baltă AAȘ, Ciortea DA, Petrea Cliveți CL, Șerban Grădinaru M, Matei MN, Gurău G, Șuța VC, Voinescu DC. Healthcare Interventions in the Management of Rheumatic Diseases: A Narrative Analysis of Effectiveness and Emerging Strategies. Healthcare (Basel). 2025;13:1691. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 4] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 149. | Rosenbaum PL. Prevention of psychosocial problems in children with chronic illness. CMAJ. 1988;139:293-295. [PubMed] |
| 150. | Memari AH, Chamanara E, Ziaee V, Kordi R, Raeeskarami SR. Behavioral Problems in Juvenile Idiopathic Arthritis: A Controlled Study to Examine the Risk of Psychopathology in a Chronic Pediatric Disorder. Int J Chronic Dis. 2016;2016:5726236. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 6] [Cited by in RCA: 17] [Article Influence: 1.7] [Reference Citation Analysis (0)] |
| 151. | Bombaci B, Torre A, Longo A, Pecoraro M, Papa M, Sorrenti L, La Rocca M, Lombardo F, Salzano G. Psychological and Clinical Challenges in the Management of Type 1 Diabetes during Adolescence: A Narrative Review. Children (Basel). 2024;11:1085. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 29] [Reference Citation Analysis (0)] |
| 152. | Gautam S, Jain A, Chaudhary J, Gautam M, Gaur M, Grover S. Concept of mental health and mental well-being, it's determinants and coping strategies. Indian J Psychiatry. 2024;66:S231-S244. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 169] [Cited by in RCA: 75] [Article Influence: 37.5] [Reference Citation Analysis (0)] |
| 153. | Sartore GM, Pourliakas A, Lagioia V. Peer support interventions for parents and carers of children with complex needs. Cochrane Database Syst Rev. 2021;12:CD010618. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 29] [Cited by in RCA: 30] [Article Influence: 6.0] [Reference Citation Analysis (2)] |
| 154. | Kholghi H, Habibi Asgarabad M, Abolmaali Alhosseini K, Dehghani F, Semple RJ. The effectiveness of mindfulness-based cognitive therapy for children on anxiety, attentional control, and emotion regulation in children: a study protocol. Front Pediatr. 2025;13:1459434. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 155. | Søvold LE, Naslund JA, Kousoulis AA, Saxena S, Qoronfleh MW, Grobler C, Münter L. Prioritizing the Mental Health and Well-Being of Healthcare Workers: An Urgent Global Public Health Priority. Front Public Health. 2021;9:679397. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 704] [Cited by in RCA: 472] [Article Influence: 94.4] [Reference Citation Analysis (0)] |
| 156. | Ginsburg GS, Schleider J, Tein JY, Drake KL. Family and Parent Predictors of Anxiety Disorder Onset in Offspring of Anxious Parents. Child Youth Care Forum. 2018;47:363-376. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 4] [Article Influence: 0.4] [Reference Citation Analysis (0)] |
| 157. | Andrews G, Bell C, Boyce P, Gale C, Lampe L, Marwat O, Rapee R, Wilkins G. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder. Aust N Z J Psychiatry. 2018;52:1109-1172. [DOI] [Full Text] |
| 158. | Sun Y, Blewitt C, Minson V, Bajayo R, Cameron L, Skouteris H. Trauma-informed Interventions in Early Childhood Education and Care Settings: A Scoping Review. Trauma Violence Abuse. 2024;25:648-662. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 8] [Cited by in RCA: 13] [Article Influence: 6.5] [Reference Citation Analysis (0)] |
| 159. | Todd JA, Knip M, Mathieu C. Strategies for the prevention of autoimmune type 1 diabetes. Diabet Med. 2011;28:1141-1143. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 14] [Cited by in RCA: 11] [Article Influence: 0.7] [Reference Citation Analysis (0)] |
| 160. | Heydarzadeh S, Abooshahab R, Zarkesh M, Hedayati M. Endocrine polyautoimmunity: Mechanistic insights and the future of AI-driven diagnostics. EXCLI J. 2025;24:1500-1519. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 161. | Schrodi SJ, Mukherjee S, Shan Y, Tromp G, Sninsky JJ, Callear AP, Carter TC, Ye Z, Haines JL, Brilliant MH, Crane PK, Smelser DT, Elston RC, Weeks DE. Genetic-based prediction of disease traits: prediction is very difficult, especially about the future. Front Genet. 2014;5:162. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 40] [Cited by in RCA: 44] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
| 162. | Katahira M, Ogata H, Ito T, Miwata T, Goto M, Nakamura S, Takashima H. Association of Autoimmune Thyroid Disease with Anti-GAD Antibody ELISA Test Positivity and Risk for Insulin Deficiency in Slowly Progressive Type 1 Diabetes. J Diabetes Res. 2018;2018:1847430. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 4] [Cited by in RCA: 9] [Article Influence: 1.1] [Reference Citation Analysis (0)] |
| 163. | Gu Y, Zhao Z, Waugh K, Miao D, Jia X, Cheng J, Michels A, Rewers M, Yang T, Yu L. High-throughput multiplexed autoantibody detection to screen type 1 diabetes and multiple autoimmune diseases simultaneously. EBioMedicine. 2019;47:365-372. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 16] [Cited by in RCA: 25] [Article Influence: 3.6] [Reference Citation Analysis (0)] |
| 164. | Leslie D, Lipsky P, Notkins AL. Autoantibodies as predictors of disease. J Clin Invest. 2001;108:1417-1422. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 130] [Cited by in RCA: 131] [Article Influence: 5.2] [Reference Citation Analysis (0)] |
| 165. | Vehik K, Lynch KF, Schatz DA, Akolkar B, Hagopian W, Rewers M, She JX, Simell O, Toppari J, Ziegler AG, Lernmark Å, Bonifacio E, Krischer JP; TEDDY Study Group. Reversion of β-Cell Autoimmunity Changes Risk of Type 1 Diabetes: TEDDY Study. Diabetes Care. 2016;39:1535-1542. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 55] [Cited by in RCA: 79] [Article Influence: 7.9] [Reference Citation Analysis (0)] |
| 166. | Kulmala P, Rahko J, Savola K, Vähäsalo P, Veijola R, Sjöroos M, Reunanen A, Ilonen J, Knip M. Stability of autoantibodies and their relation to genetic and metabolic markers of Type I diabetes in initially unaffected schoolchildren. Diabetologia. 2000;43:457-464. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 17] [Cited by in RCA: 16] [Article Influence: 0.6] [Reference Citation Analysis (0)] |
| 167. | Fulda KG, Lykens K. Ethical issues in predictive genetic testing: a public health perspective. J Med Ethics. 2006;32:143-147. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 86] [Cited by in RCA: 62] [Article Influence: 3.1] [Reference Citation Analysis (0)] |
| 168. | Jesuthasan J, Watson CJ, Hafeez D, Lynch-Kelly K, Danese A, Pollak TA. Childhood adversity as a risk factor for autoimmune disease: A systematic review and meta-analysis with implications for psychiatry. Brain Behav Immun. 2025;128:643-653. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 169. | Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. BMJ. 2001;322:1052-1056. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 141] [Cited by in RCA: 140] [Article Influence: 5.6] [Reference Citation Analysis (0)] |
| 170. | Warrilow A, Morton M. Autoimmune disorders in child psychiatry: keeping up with the field. BJPsych Adv. 2015;21:367-376. [RCA] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 171. | Gutierrez-Achury J, Romanos J, Bakker SF, Kumar V, de Haas EC, Trynka G, Ricaño-Ponce I, Steck A; Type 1 Diabetes Genetics Consortium, Chen WM, Onengut-Gumuscu S, Simsek S; Diabeter, Rewers M, Mulder CJ, Liu E, Rich SS, Wijmenga C. Contrasting the Genetic Background of Type 1 Diabetes and Celiac Disease Autoimmunity. Diabetes Care. 2015;38 Suppl 2:S37-S44. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 47] [Cited by in RCA: 39] [Article Influence: 3.5] [Reference Citation Analysis (1)] |
| 172. | Naredi Scherman M, Melin J, Agardh D. Celiac disease screening in children: evaluating the evidence, benefits, and challenges. Front Pediatr. 2025;13:1562073. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 173. | Callahan KP, Clayton EW, Lemke AA, Chaudhari BP, Wenger TL, Lyle ANJ, Brothers KB. Ethical and Legal Issues Surrounding Genetic Testing in the NICU. Neoreviews. 2024;25:e127-e138. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 8] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 174. | Hercher L. Discouraging Elective Genetic Testing of Minors: A Norm under Siege in a New Era of Genomic Medicine. Cold Spring Harb Perspect Med. 2020;10:a036657. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 9] [Cited by in RCA: 15] [Article Influence: 2.5] [Reference Citation Analysis (0)] |
| 175. | Hatun Ş, Dalgıç B, Gökşen D, Aydoğdu S, Savaş Erdeve Ş, Kuloğu Z, Doğan Y, Aycan Z, Yeşiltepe Mutlu G, Uslu Kızılkan N, Keser A, Beşer ÖF, Özbek MN, Bideci A, Ertem D, Evliyaoğlu O, Eliuz Tipici B, Gökçe T, Muradoğlu S, Taşkın OÇ, Koca T, Tütüncüler F, Baş F, Darendeliler F, Selimoğlu MA. Recommendations for Clinical Decision-making in Children with Type 1 Diabetes and Celiac Disease: Type 1 Diabetes and Celiac Disease Joint Working Group Report. J Clin Res Pediatr Endocrinol. 2022;14:1-9. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 176. | Tian T, Aaron RE, DuNova AY, Jendle JH, Kerr D, Cengiz E, Drincic A, Pickup JC, Chen KY, Schwartz N, Muchmore DB, Akturk HK, Levy CJ, Schmidt S, Bellazzi R, Wu AHB, Spanakis EK, Najafi B, Chase JG, Seley JJ, Klonoff DC. Diabetes Technology Meeting 2023. J Diabetes Sci Technol. 2024;18:1208-1244. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 3] [Article Influence: 1.5] [Reference Citation Analysis (0)] |
| 177. | France E, Uny I, Turley R, Thomson K, Noyes J, Jordan A, Forbat L, Caes L, Silveira Bianchim M. A meta-ethnography of how children and young people with chronic non-cancer pain and their families experience and understand their condition, pain services, and treatments. Cochrane Database Syst Rev. 2023;10:CD014873. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 8] [Reference Citation Analysis (0)] |
| 178. | Dahlquist LM, Pendley JS. When distraction fails: parental anxiety and children's responses to distraction during cancer procedures. J Pediatr Psychol. 2005;30:623-628. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 40] [Cited by in RCA: 40] [Article Influence: 1.9] [Reference Citation Analysis (0)] |
| 179. | Akbari H, Mohammadi M, Hosseini A. Disease-Related Stigma, Stigmatizers, Causes, and Consequences: A Systematic Review. Iran J Public Health. 2023;52:2042-2054. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 14] [Reference Citation Analysis (0)] |
| 180. | Grootens-Wiegers P, Hein IM, van den Broek JM, de Vries MC. Medical decision-making in children and adolescents: developmental and neuroscientific aspects. BMC Pediatr. 2017;17:120. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 109] [Cited by in RCA: 197] [Article Influence: 21.9] [Reference Citation Analysis (0)] |
| 181. | Edvardsson M, Heenkenda MK. Precision Medicine: Personalizing Healthcare by Bridging Aging, Genetics, and Global Diversity. Healthcare (Basel). 2025;13:1529. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 182. | Pongdee T, Brunner WM, Kanuga MJ, Sussman JH, Wi CI, Juhn YJ. Rural Health Disparities in Allergy, Asthma, and Immunologic Diseases: The Current State and Future Direction for Clinical Care and Research. J Allergy Clin Immunol Pract. 2024;12:334-344. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 8] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 183. | Ibáñez A, Duran-Aniotz C, Migeot J, Báez S, Fittipaldi S, Coronel-Oliveros C, Eyre HA, Udeh-Momoh C, Zetterberg H, Alladi S, Sandi C, Robertson IH, Franzen S, Farombi T, Montalvo Ortiz JL, Seshadri S, Court F, Valdes-Sosa P, Xu J, Yu C, Grinberg L, Lawlor B, Sachdev PS, Yaffe K, Hachinski V, Friston K, Tagliazucchi E, Santamaría-García H. Computational whole-body-exposome models for global precision brain health. Nat Commun. 2025;16:11078. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 13] [Reference Citation Analysis (0)] |
| 184. | Ofori B, Twum S, Nkansah Yeboah S, Ansah F, Amofa Nketia Sarpong K. Towards the development of cost-effective point-of-care diagnostic tools for poverty-related infectious diseases in sub-Saharan Africa. PeerJ. 2024;12:e17198. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 9] [Reference Citation Analysis (0)] |
| 185. | Jansen SNG, Kamphorst BA, Mulder BC, van Kamp I, Boekhold S, van den Hazel P, Verweij MF. Ethics of early detection of disease risk factors: A scoping review. BMC Med Ethics. 2024;25:25. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 16] [Article Influence: 8.0] [Reference Citation Analysis (0)] |
| 186. | Jörg S, Grohme DA, Erzler M, Binsfeld M, Haghikia A, Müller DN, Linker RA, Kleinewietfeld M. Environmental factors in autoimmune diseases and their role in multiple sclerosis. Cell Mol Life Sci. 2016;73:4611-4622. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 78] [Cited by in RCA: 87] [Article Influence: 8.7] [Reference Citation Analysis (0)] |
| 187. | Ozdemir C, Kucuksezer UC, Ogulur I, Pat Y, Yazici D, Ardicli S, Akdis M, Nadeau K, Akdis CA. Lifestyle Changes and Industrialization in the Development of Allergic Diseases. Curr Allergy Asthma Rep. 2024;24:331-345. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 36] [Reference Citation Analysis (0)] |
| 188. | Alves Abrantes JJP, Veríssimo de Azevedo JC, Fernandes FL, Duarte Almeida V, Custódio De Oliveira LA, Ferreira de Oliveira MT, Galvão De Araújo JM, Lanza DCF, Bezerra FL, Andrade VS, Araújo de Medeiros Fernandes TA, Fernandes JV. Viruses as a potential environmental trigger of type 1 diabetes mellitus (Review). Biomed Rep. 2024;20:81. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 12] [Cited by in RCA: 9] [Article Influence: 4.5] [Reference Citation Analysis (0)] |
| 189. | Jaskulski S, Nuszbaum C, Michels KB. Components, prospects and challenges of personalized prevention. Front Public Health. 2023;11:1075076. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 18] [Reference Citation Analysis (0)] |
| 190. | Pandya A, Parashar S, Waller M, Portnoy J. Telemedicine beyond the pandemic: challenges in the pediatric immunology clinic. Expert Rev Clin Immunol. 2023;19:1063-1073. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 3] [Article Influence: 1.0] [Reference Citation Analysis (0)] |
| 191. | Rad J. Health inequities: a persistent global challenge from past to future. Int J Equity Health. 2025;24:148. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 25] [Reference Citation Analysis (0)] |
| 192. | Liu S, Zhu M, Yi C, Zeng D. Early rehabilitation interventions for global developmental delay in children: a narrative review. Front Pediatr. 2025;13:1576324. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 193. | Abdi YH, Abdi MS, Bashir SG, Ahmed NI, Abdullahi YB. Understanding Global Health Inequality and Inequity: Causes, Consequences, and the Path Toward Justice in Healthcare. Public Health Chall. 2025;4:e70156. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 6] [Reference Citation Analysis (0)] |
| 194. | Mazzucca CB, Raineri D, Cappellano G, Chiocchetti A. How to Tackle the Relationship between Autoimmune Diseases and Diet: Well Begun Is Half-Done. Nutrients. 2021;13:3956. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 29] [Article Influence: 5.8] [Reference Citation Analysis (0)] |
| 195. | Scarpa G, Berrang-Ford L, Twesigomwe S, Kakwangire P, Galazoula M, Zavaleta-Cortijo C, Patterson K, Namanya DB, Lwasa S, Nowembabazi E, Kesande C; IHACC Research Team, Cade JE. Socio-economic and environmental factors affecting breastfeeding and complementary feeding practices among Batwa and Bakiga communities in south-western Uganda. PLOS Glob Public Health. 2022;2:e0000144. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5] [Cited by in RCA: 13] [Article Influence: 3.3] [Reference Citation Analysis (0)] |
| 196. | Idris IB, Syed Soffian SS, Baharom M, Baharuddin UM, Hashim S, Nawi AM. Influence of sociocultural beliefs and practices on contraception: a systematic review. Women Health. 2022;62:688-699. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 197. | Cooper S, Schmidt BM, Sambala EZ, Swartz A, Colvin CJ, Leon N, Wiysonge CS. Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2021;10:CD013265. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 13] [Cited by in RCA: 51] [Article Influence: 10.2] [Reference Citation Analysis (0)] |
| 198. | Sprengholz P, Felgendreff L, Böhm R, Betsch C. Vaccination policy reactance: Predictors, consequences, and countermeasures. J Health Psychol. 2022;27:1394-1407. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 9] [Cited by in RCA: 49] [Article Influence: 9.8] [Reference Citation Analysis (0)] |
| 199. | Vandecasteele R, Robijn L, Willems S, De Maesschalck S, Stevens PAJ. Barriers and facilitators to culturally sensitive care in general practice: a reflexive thematic analysis. BMC Prim Care. 2024;25:381. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 36] [Cited by in RCA: 23] [Article Influence: 11.5] [Reference Citation Analysis (0)] |
| 200. | Alnafisah RY, Alragea AS, Alzamil MK, Alqahtani AS. The Impact and Efficacy of Vitamin D Fortification. Nutrients. 2024;16:4322. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 17] [Reference Citation Analysis (8)] |
| 201. | Bernal G, Jiménez-Chafey MI, Domenech Rodríguez MM. Cultural adaptation of treatments: A resource for considering culture in evidence-based practice. Prof Psychol Res Pr. 2009;40:361-368. [DOI] [Full Text] |
| 202. | Marsiglia FF, Booth JM. Cultural Adaptation of Interventions in Real Practice Settings. Res Soc Work Pract. 2015;25:423-432. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 97] [Cited by in RCA: 113] [Article Influence: 10.3] [Reference Citation Analysis (0)] |
| 203. | Sarigiannis D, Karakitsios S, Anesti O, Stem A, Valvi D, Sumner SCJ, Chatzi L, Snyder MP, Thompson DC, Vasiliou V. Advancing translational exposomics: bridging genome, exposome and personalized medicine. Hum Genomics. 2025;19:48. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 37] [Cited by in RCA: 28] [Article Influence: 28.0] [Reference Citation Analysis (0)] |
| 204. | Ayoub A, McHugh J, Hayward J, Rafi I, Qureshi N. Polygenic risk scores: improving the prediction of future disease or added complexity? Br J Gen Pract. 2022;72:396-398. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 13] [Reference Citation Analysis (0)] |
| 205. | Gauderman WJ, Fu Y, Queme B, Kawaguchi E, Wang Y, Morrison J, Brenner H, Chan A, Gruber SB, Keku T, Li L, Moreno V, Pellatt AJ, Peters U, Samadder NJ, Schmit SL, Ulrich CM, Um C, Wu A, Lewinger JP, Drew DA, Mi H. Pathway Polygenic Risk Scores (pPRS) for the Analysis of Gene-environment Interaction. bioRxiv. 2024;2024.12.16.628610. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 4] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 206. | Qu HQ, Qu J, Bradfield J, Glessner J, Chang X, March M, Mentch FD, Roizen JD, Connolly JJ, Sleiman P, Hakonarson H. Combined application of genetic and polygenic risk scores for type 1 diabetes risk prediction. Diabetes Obes Metab. 2021;23:2001-2003. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 207. | Lim AJW, Tyniana CT, Lim LJ, Tan JWL, Koh ET; TTSH Rheumatoid Arthritis Study Group, Chong SS, Khor CC, Leong KP, Lee CG. Robust SNP-based prediction of rheumatoid arthritis through machine-learning-optimized polygenic risk score. J Transl Med. 2023;21:92. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 17] [Reference Citation Analysis (0)] |
| 208. | Wang Y, Tsuo K, Kanai M, Neale BM, Martin AR. Challenges and Opportunities for Developing More Generalizable Polygenic Risk Scores. Annu Rev Biomed Data Sci. 2022;5:293-320. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 72] [Cited by in RCA: 132] [Article Influence: 33.0] [Reference Citation Analysis (0)] |
| 209. | Safarlou CW, Jongsma KR, Vermeulen R, Bredenoord AL. The ethical aspects of exposome research: a systematic review. Exposome. 2023;3:osad004. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 19] [Article Influence: 6.3] [Reference Citation Analysis (0)] |
| 210. | Henches L, Kim J, Yang Z, Rubinacci S, Pires G, Albiñana C, Boetto C, Julienne H, Frouin A, Auvergne A, Suzuki Y, Djebali S, Delaneau O, Ganna A, Vilhjálmsson B, Privé F, Aschard H. Polygenic risk score prediction accuracy convergence. HGG Adv. 2025;6:100457. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 211. | Ullah H, Tovchiga O, Daglia M, Khan H. Modulating Gut Microbiota: An Emerging Approach in the Prevention and Treatment of Multiple Sclerosis. Curr Neuropharmacol. 2021;19:1966-1983. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 9] [Cited by in RCA: 17] [Article Influence: 3.4] [Reference Citation Analysis (0)] |
| 212. | Abouelela ME, Helmy YA. Next-Generation Probiotics as Novel Therapeutics for Improving Human Health: Current Trends and Future Perspectives. Microorganisms. 2024;12:430. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 173] [Cited by in RCA: 119] [Article Influence: 59.5] [Reference Citation Analysis (2)] |
| 213. | Jadhav NK, Magdum AB, Shinde KV, Nimbalkar MS. Next-Generation Probiotics: From Traditional Strains to Personalized Therapeutics. Mol Nutr Food Res. 2026;70:e70339. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 7] [Cited by in RCA: 9] [Article Influence: 9.0] [Reference Citation Analysis (0)] |
| 214. | Kezer G, Paramithiotis S, Khwaldia K, Harahap IA, Čagalj M, Šimat V, Smaoui S, Elfalleh W, Ozogul F, Esatbeyoglu T. A comprehensive overview of the effects of probiotics, prebiotics and synbiotics on the gut-brain axis. Front Microbiol. 2025;16:1651965. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 22] [Reference Citation Analysis (0)] |
| 215. | Effendi RMRA, Anshory M, Kalim H, Dwiyana RF, Suwarsa O, Pardo LM, Nijsten TEC, Thio HB. Akkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases. Microorganisms. 2022;10:2382. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 135] [Cited by in RCA: 119] [Article Influence: 29.8] [Reference Citation Analysis (7)] |
| 216. | Zeng L, Deng Y, Yang K, Chen J, He Q, Chen H. Safety and efficacy of fecal microbiota transplantation for autoimmune diseases and autoinflammatory diseases: A systematic review and meta-analysis. Front Immunol. 2022;13:944387. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 39] [Cited by in RCA: 38] [Article Influence: 9.5] [Reference Citation Analysis (0)] |
| 217. | Sundaresan B, Shirafkan F, Ripperger K, Rattay K. The Role of Viral Infections in the Onset of Autoimmune Diseases. Viruses. 2023;15:782. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 122] [Reference Citation Analysis (0)] |
| 218. | Vadalà M, Poddighe D, Laurino C, Palmieri B. Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J. 2017;8:295-311. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 128] [Cited by in RCA: 107] [Article Influence: 11.9] [Reference Citation Analysis (0)] |
| 219. | Cusick MF, Libbey JE, Fujinami RS. Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol. 2012;42:102-111. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 502] [Cited by in RCA: 428] [Article Influence: 30.6] [Reference Citation Analysis (7)] |
| 220. | Dahl-Jørgensen K. Virus as the cause of type 1 diabetes. Trends Mol Med. 2024;30:1020-1027. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 19] [Cited by in RCA: 18] [Article Influence: 9.0] [Reference Citation Analysis (0)] |
| 221. | Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmøy T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis - association and causation. Viruses. 2012;4:3701-3730. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 89] [Cited by in RCA: 93] [Article Influence: 7.2] [Reference Citation Analysis (0)] |
| 222. | Hedström AK. Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection. Front Immunol. 2023;14:1212676. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 43] [Reference Citation Analysis (0)] |
| 223. | Smith C, Khanna R. The Development of Prophylactic and Therapeutic EBV Vaccines. Curr Top Microbiol Immunol. 2015;391:455-473. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 7] [Cited by in RCA: 14] [Article Influence: 1.3] [Reference Citation Analysis (0)] |
| 224. | Bordin DS, Livzan MA, Mozgovoi SI, Gaus OV. Autoimmune Gastritis and Helicobacter pylori Infection: Molecular Mechanisms of Relationship. Int J Mol Sci. 2025;26:7737. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 7] [Reference Citation Analysis (0)] |
| 225. | Torres N, Tovar AR. The present and future of personalized nutrition. Rev Invest Clin. 2021;73:321-325. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 4] [Article Influence: 0.8] [Reference Citation Analysis (0)] |
| 226. | Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. Cold Spring Harb Mol Case Stud. 2015;1:a000588. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 601] [Cited by in RCA: 480] [Article Influence: 43.6] [Reference Citation Analysis (0)] |
| 227. | Kim M, Lee S, Hur J, Shin D. Metabolomics and nutrient intake reveal metabolite-nutrient interactions in metabolic syndrome: insights from the Korean Genome and Epidemiology Study. Nutr J. 2025;24:128. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 4] [Cited by in RCA: 7] [Article Influence: 7.0] [Reference Citation Analysis (0)] |
| 228. | Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. Microorganisms. 2019;7:14. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2934] [Cited by in RCA: 2396] [Article Influence: 342.3] [Reference Citation Analysis (13)] |
| 229. | Heuven LA, Pyle S, Greyling A, Melse-Boonstra A, Eilander A. Gut Microbiota-Targeted Nutritional Interventions Improving Child Growth in Low- and Middle-Income Countries: A Systematic Review. Curr Dev Nutr. 2021;5:nzab124. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 4] [Cited by in RCA: 14] [Article Influence: 2.8] [Reference Citation Analysis (0)] |
| 230. | Alkuwaiti SH, Skrabulyte-Barbulescu J, Yassin LK, Almazrouei S, Aldhaheri D, Alderei M, BaniYas S, Alshamsi SH, Alnuaimi A, Saeed S, Alawadhi M, Rutkowska-Gauvry P, Ismail FY, Hamad MIK. Harnessing the microbiota-gut-brain axis to prevent and treat pediatric neurodevelopmental disorders: translational insights and strategies. J Transl Med. 2025;23:1286. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 11] [Cited by in RCA: 11] [Article Influence: 11.0] [Reference Citation Analysis (0)] |
| 231. | Zhang P. Influence of Foods and Nutrition on the Gut Microbiome and Implications for Intestinal Health. Int J Mol Sci. 2022;23:9588. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 241] [Reference Citation Analysis (7)] |